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 INTRODUCTION   1 
 Siddha system of medicine is one of the ancient and holistic medical system in the 
world.  Siddha system deals with physical as well as mental health.  Siddhars were 
spiritual scientists who possessed the “Ashtama Siddhis” (eight supernatural powers).  
With their siddhis, they find out the ways to attain peaceful, healthy, long life and even 
eternity. 
             In olden days, there were 18 siddhars who developed siddha medicine as a 
systematic medical system. Siddha medicines are prepared using herbs, metals, minerals 
and animal products as raw drug. 
 Siddha medical system uses chemico-metallurgical raw drugs of 212 varieties 
namely mercury, sulphur, arsenic, minerals etc. The drugs undergo many process like 
incineration or sublimation and again triturated.  The final product which are higher order 
form of medicine like chenduram, parpam, etc.  It has physical-chemical transformation, 
reduction in particle size, long duration of shelf life, efficacy enhancement, reduced 
toxicity level. 
 “SWARNA PUSHPA RASA CHENDHURAM” is one of the Chendhuram 
selected here as trial drug for the study in psoriasis.  
 Psoriasis is common, non-contagious and chornic skin disease characterized by 
well demarcated slightly raised, dry erythematous macules with slivery scales and typical 
extensor distribution. Most often on the elbows, knees, scalp, hands and feet.  It is 
pandemic in temperate climate.  Onset between 20-30 yrs. of this1,50,000-2,60,000 new 
cases of psoriasis are diagnosed each year.  About 400 people die from complications 
caused by psoriasis every year.   About 11% patients have psoriatic arthritis. 
             Among all the diseases affecting human beings, skin diseases are the most 
challenging. As skin plays a major role in the appearance of an individual skin diseases 
affect a person not only physically but also mentally. So treatment should be given for 
both physical and mental strength. Many skin disease are classified by siddhars brought 
1.  INTRODUCTION 
 INTRODUCTION   2 
under “KUTTAM”. There are 18 types of kuttam in “YUGIMUNI” from these types  
(Thethuru kuttam) “Thadippu Perunoi” resembles  the skin disease “PSORIASIS”. 
  The dry erythematous macules of skin in psoriasis can be itchy and 
uncomfortable. Topical application with oil based may give greasy and moisture effect. 
Herbs in  “VETTIVER THYLAM” removes dead skin and allows the medication to work 
better. 
               Stress is a common trigger for a psoriasis flare.  Psoriasis flare can cause stress. 
So stress management should be part of any treatment plan.  Pranayamam is the science 
of breathing. Pranayamam brings back to parasympathetic nervous system which is 
responsible for relaxation and restorative processes.  Pranayamam lowers the level of 
cortisol, increases the level of melatonin and serotonin.  Pranayamam may have treating 
ability of psoriasis by reducing stress.  So “PRANAYAMAM” is included in this study to 
create a complete treatment plan for psoriasis. 
  The concern of this study is to get subjective as well as clinical improvement by 
pharmacotherapy with “SWARNA PUSHPA RASA CHENDHURAM” (INTERNAL), 
“VETTIVER THYLAM” (EXTERNAL) and breathing therapy with “PRANAYAMAM” 
in the management of psoriasis. 
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2. AIM AND OBJECTIVES 
AIM: 
To evaluate the safety and efficacy of Herbo metallic Siddha Drugs “Swarna Pushpa 
Rasa Chendhuram” (Internal), “Vettiver Thylam” (External) & “Pranayamam” in 
management of Thadippu Perunoi (Psoriasis). 
PRIMARY OBJECTIVES: 
To evaluate the efficacy of the Siddha Trial Drugs “Swarna Pushpa Rasa 
Chendhuram” (Internal), “Vettiver Thylam” (External) & “Pranayamam” in Thadippu 
Perunoi (Psoriasis). 
SECONDARY OBJECTIVES: 
 To study the safety profile of trial drug Swarna Pushpa Rasa 
Chendhuram (Internal). 
 To discuss the various literature evidences of Thadippu Perunoi in 
Siddha Medicine and Psoriasis in modern science. 
 To Study the Siddha purification method of raw drugs. 
 To get the authentication of the raw drugs. 
 To standardize the standard operating procedure. 
 To Study the physico- chemical analysis of the selected trial drug. 
 To study the acute & sub - acute toxicity of the trial drug Swarna Pushpa 
Rasa Chendhuram according to OECD guidelines. 
 To analyze the pharmacological activities of the selected trial drug. 
 To estimate the quantity of heavy metals analysis in the trial drug. 
 To evaluate the safety of the trial drug Swarna Pushpa Rasa Chendhuram 
in Psoriasis patients before and after treatment. 
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3.  REVIEW OF LITERATURES 
 
3.1. SIDDHA ASPECT OF DISEASE( THADIPPU PERUNOI) 
The skin diseases are classified as 18 in Siddha System of Medicine. Thesediseases 
are commonly classified under Kuttam. They are otherwise known as   Perunoi. So 
the term is used for various skin disease like Psoriasis, Vitiligo, Eczema, Hansen’s  
disease , etc
1
. 
,ay;
1
: 
 Fl;l Nehapy; cly; kpDkpDj;jy; gilfSz;lhjy;> foiyfs; 
fhZjy;> if fhy;fspd; tpuy;fs; mOFjy; my;yJ mitfs; tise;J 
Fiwjy; Mfpa ,ay;GilajhFk;. 
 Fw;wq;fs; Kjd; Kjypy; FUjpiaAk;> ,uz;lhtjhf rijiaAk; 
jhf;fp gpd;dh; Njhypd; topahf ntspg;gLk; ,ay;Gila Neha; MFk;. 
AETIOLOGY: 
In the Siddha literature “Thirumular Vaithiyam” Said in 
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In the Siddha literatures “Guru Naadi Nool” Said in 
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In the Siddha literatures “THANVANTHIRI VAITHIYAM” Said in   
             4 
“                                
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In the Siddha literatures “AGATHIYAR KANMA KANDAM” Said in  
   
            5 
      “                            
                                    
                                 
                              “. 
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                    
                          
                                    . 
CLASSIFICATION OF KUTTAM: 
According to YUGIMUNI Kuttam are 18 types
6 
These are 
“                          
                          
                         
                     . . . . . . . . . . . . . . . . . . . . . . . . . .  
                             
                         ”. 
       : 
1.       
2.         
3.      
4.       
5.      
6.     
7.      
8.        
9.      
10.       
11.          
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12.         
13.      
14.        
15.      
16.       
17.      
18.       
In the Siddha literature “Siddhar Aruvai Maruthuvam” Said in 
                    7: 
                                   
        
1.         
2.         
3.         
4.           
5.            
6.             
7.           . 
   1.                  :           
2.                                  
3.                               
                      
4.                          
5.                             
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6.                          
                   
               
           
             
7.                             
             
                
                 
            
            
          . 
 
T. V. SAMBASIVAM PILLAI Authors classify this disease only under 8 varieties
8 
      They are   
1. Blisters in feet 
2. Deformity of generative organs 
3. Cutaneous fissures 
4. Elephantiasis 
5. Ulcers 
6. Coppery blotches -  lepra maculosa 
7. Black leprosy – lepra graecorum 
8. White leprosy – lepra mosaic 
       எ                 :              :    6 
    
1.          
2.      
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3.        
4.        
5.         
6.      
7.       
8.      
9.      
10.     . 
According to Yugimuni Thethutru Kuttam (Psoriasis) is curable. 
        எ                 : எ  6 
        
1.        
2.      
3.      
4.       
5.       
6.          
7.         
8.       
Psoriasis symptoms are co-related with features of Thadippu Perunoi (Thethuru 
Kuttam) in “YUGI VAITHIYA CHINTHAMANI”9 
           
            “                        
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                         .” 
 
Explanations : 
                                -Coin shaped lesion 
                      - White silvery scales. 
          - Erythematous 
             – Itching 
                      – Curling of hair 
                                          . 
                
In THETHURU KUTTAM(THADIPPU PERUNOI) nowadays said in Siddha 
system of medicine was KALANJAGAPADAI (Psoriasis) 
 
         10: 
                 
                
               
              
                            
                              
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 “                                  
                                 
                                
                                     
                               
                                            
                              
                                        ” 
                             
                                          
                                           
                   – Pain present in all joints 
                                               
-Restricted movements. 
                    - Difficulty in walking 
              - Anemia 
         -Itching 
               - Pustules 
                                    
       . 
  REVIEW OF LITERATURES    13 
        1: 
                        ,                  
        . 
              ,                            
                                       . 
                                       12 
                                      
                        . 
          10: 
                                          
                          . 
                                             
                                   . 
                                            
                 . 
                                         
                           
                                        
         . 
                         . 
                      . 
               . 
                                        . 
  REVIEW OF LITERATURES    14 
                                       . 
                                  . 
                                          
                    . 
                                . 
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METALS AND MINERALS USED TO TREAT KUTTAM
1
: 
 Gandhagam (Sulphur) 
 Thambiram (Copper) 
 Vangam (Stannum) 
 Thalagam (Arsenic sulphide) 
 Rasam (Mercury) 
 Thurusu (Copper sulphate) 
 Ayam (Iron) 
 Palagarai (Marine shell) 
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The trial drug SwarnaPushpa Rasa Chenduramcontains 3 of the above said drugs. 
 
These are 
1. Rasam 
2. Gandhagam 
3. Vangam 
HERBAL DRUGS USED TO TREAT KUTTAM : 
1. Serangottai 
2. Neeradimuthu 
3. Sivanarvembu 
4. Kaarbogi 
5. Vetpaalai 
6. Pungu 
DIET RESTRICTION (PATTHIYAM)
1
: 
1. Fish, crab, prawn are some seafoods should be avoided. 
2. Curd, Jaggery, oil, White gram should be avoided. 
3. Non vegetarian diet should be avoided.  
4. Alcohol beverages should be avoided. 
5. Brinjal should be avoided. 
6. In severe cases tamarind should be avoided. 
7. Dietary taken salt in minimum quantities. 
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3.2. MODERN ASPECT OF DISEASE 
ANATOMY OF SKIN
4
: 
The skin is the protective covering of the body, Skin which covers the entire surface 
of the human body. The human skin shows 2 wide variations in structure. 
1. Thick skin found in Scalp 
                                 Ear lobes 
                                 Palms 
      Soles 
2. Thin skin over the rest of the body. 
 The average thickness of the skin is about 1 to 2 mm. 
 In the sole of the foot, palm of the hand and in the inter scapular 
region, it is considerably thick measuring about 5 mm. 
 Skin is very thinnest in eyelids and penis measuring about 0.5mm only. 
 
The skin is composed of a 
 Superficial epithelial layer – The epidermis 
 Connective tissue layer – The dermis or Corium 
 Another Connective tissue layer loose in texture – The hypodermis or 
subcutaneous layer 
STRUCTURE OF EPIDERMIS: 
 The epidermis is formed of non vascular stratified epithelium. 
 The average thickness of the skin is between 0.07 mm to0.12 mm. 
 Certain parts like the soles of the feet and the palms of the hands it is 
very thick ranging from 0.8mm to1.4mm. 
 Squamous epithelium is 10 to 11 cells thick in the palms and soles. 
 Squamous epithelium is 3 to 4 cells over the eyelids. 
 The nutrition is provided to epidermis by the capillaries of dermis. 
The epidermis is mainly divided into two main systems, 
1. Malpighian system which forms the bulk (Keratinocytes) 
2. Pigmentary system which produce pigment ( Melanocytes) 
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In addition of four types of cells. These are 
1. Keratinocytes 
2. Melanocytes 
3. Langerhans cell 
4. Intermittent cells 
          In the epidermis, another unique cell known as Markel cell or Haascheiben or 
Touch cells here found at the base of epidermal ridges, which are in contact with 
nerve fibers, they are mostly present in palms, soles, nail beds, oral and genital 
epithelium, and act as slow touch receptors. 
LAYERS OF EPIDERMIS: 
          Epidermis layer can be made out microscopically in a section of perpendicular 
to the skin surfaces, the following 5 main layers of the epidermis. 
            These are 
1. Stratum germinatum 
2. Stratum malpighii 
3. Stratum granulosum 
4. Stratum lucidum 
5. Stratum corneum. 
 
1. SRATUM  GERMINATUM: 
 This is the deepest potion of the epidermis and it is composed of 
columnar cells placed perpendicular to the skin surface, it is also known as 
basal cell layer.The whole of the epidermis germinates from this stratum hence 
the name “Stratum Germinatum”Any trauma to this layer would result in 
scarring; trauma above the level of this layer heals without 
scarring.Melanoblasts or melanocytes are found in this layer.Stratum 
Germinatum contain granules of pigment called melanin. 
 
2. STRATUM  SPINOSUM: 
 It is also known as stratum malpighii or the prickle cell layer.It is 
superficial to the basal cell layer.It is composed of several layers of polyhedral 
  REVIEW OF LITERATURES    22 
cells connected to each other by intercellular bridges.Desmosomes present in 
this layer only. 
  
 Half size desmosomes occur on the under surface on the under surface 
of the basal cells, which play an important part in the anchoring the epidermis 
and dermis.All keratinocytes adhere together by desmosomes. 
 
3. STRATUM  GRANULOSUM: 
 It is superficial to the stratum malpighii. It is composed of flat, 
fusiform cells which are one to three layers thick, the. Cells contain irregular 
granules of keratohyalin and lysosomal enzymes and cystine rich 
proteins.Lamellar granules also known as odland bodies.These odland bodies 
take part in the waterproof barrier function of the epidermal permeability. 
 
4. STRATUM  LUCIDUM: 
 Superficial to the stratum granulosum.It is pale, wavy looking layer 
known as stratum iucidum. It is made up of many layers of flattened epithelial 
cells.This layer contains refractile droplets of eleidin. 
 
5. STRATUM CORNEUM: 
 This is the most superficial layer, the outer surface of which is exposed 
to the atmosphere.It is also known as horny layer. It is outer most layers and 
consists of dead cells, which are called as corneocytes.It consists of many 
layers of non nucleated, flattened, cornfield cells.  It is this layer which 
becomes thicker with the application of intermittent mechanical pressure.This 
layer is thickest in the palms of the hands and the soles of the feet, but thinnest 
on the outer surface of the lips, on the glans penis and the eyes. 
DENDRITIC CELLS OF EPIDERMIS: 
 These are melanocytes, Langerhans cells, and indeterminate cells.  The 
melanocytes are the pigment producing cells and are derived in foetal life from neural 
crest.  The cells of langherhans are found about the middle of epidermis. 
 The junction of epidermis and dermis is formed by basement membrane(Basal 
lamina). 
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DERMIS: (CUTIS VERA OR CORIUM) 
 Dermis is profusely supplied with blood vessels, Thickness of dermis is 1 to 3 
mm, it is made up of dense collagen fibers and fibroblasts. The collagen fibers contain 
the enzyme collagenase which is responsible for wound healing. 
             Dermis is made up of 2 layer, these are 
1. Superficial papillary layer 
2. Deeper reticular layer 
1. SUPERFICIAL  PAPILLARY  LAYER: 
  The layer projects in to the epidermis, it contains blood vessels, 
lymphatics and nerve fibers.  Dermal papillae are finger like projections arising 
from the superficial papillary dermis. 
 
2. DEEPER RETICULAR LAYER: 
  It is made up of reticular and elastic fibers.It is found around the hair, 
sweat glands and sebaceous glands.It also contain mast cells, Nerve ending, 
lymphatics and fibroblasts. 
 
APPENDAGES OF THE SKIN: 
The appendages of the skin are five these are, 
1. Sweat gland 
2. Sebaceous gland 
3. Hair 
4. Arrector pili muscle 
5. Nails. 
 
1. SWEAT GLAND: 
These are 2 types 
i. Eccrine gland 
ii. Apocrine gland 
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i.  ECCRINE GLAND: 
 They are the ordinary, small sized 0.3 mm to 0.4 mm.Sweat glands are 
distributed all over the skin except on the beds of nail, margins of lips and the glans 
penis. Over 3 million sweat gland present at birth. 
ii. APOCRINE GLAND:  
              Glandular portion is very large and may measure 3 mm to 5 mm in diameter. 
 They occur in the axilla, areola and nipples of breasts, umbilicus, around the 
anus and the genitalia.They are specialized sweat glands, and their secretion is 
odoriferous with secondary sexual significance. 
2. SEBACEOUS GLAND: 
 They are scattered all over the integument in association with the hair 
follicles.They are absent from the hairless portions of the body like the palms of the 
hands, the soles of the feet.The ducts of the sebaceous glands are lined by stratified 
squamous epithelium which is continuous with the external sheath of the hair, and 
with the malpighian layer of epidermis. 
3. HAIR: 
 Hair is fund on almost every part of the body surface except on the palms, 
soles, the dorsal surface of the terminal phalanges, the inner surface of the labia, the 
inner surface of the prepuce and the glans penis.Hairs differ in length, thickness and 
colour in different parts of the body and in different races.There are three types of 
hair, long, short, thick bristles.Hair grows about 1-2 cm per month. 
 Hair follicle and its hair can be anatomically divided in to 3 segments 
                 Infundibulam 
                 Isthumus 
                 Inferior 
4. ARRECTOR PILI: 
 Arrector pili muscles are the small bundles of plain muscles fibers, which is 
extend from the connective tissue sheath of the hair follicles to the 
epidermodermal junction.When these contract under the effect of cold or 
emotions.They move the hair into a more vertical portion is called appearance of 
“ghoose flesh”. 
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5. NAILS: 
 These are semi transparent, plate like horny structure, covering the dorsal 
surfaces of the distal phalanges of the fingers and toes.Nail parts are : 
                     Root 
                     Nail plate 
                     Nail bed 
                     Lunula 
 Lateral and posterior nail fold 
BLOOD VESSELS OF SKIN
12
: 
 The blood supply of the skin originates from the large number of arteries 
forming anastomosis in the deepest part of the dermis. From the single vessels run 
upwards and form a second network in the upper dermis.Finally terminal arterioles 
ascend in to the papillae ending in capillary loops, which drain into connective 
venules.The blood is returned to the large veins in the subcutaneous tissues. 
LYMPHATICS OF THE SKIN
12
:      
 The skin contains a rich network of lymphatics which drains in to a larger 
vessel in the hypodermis. 
NERVE SUPPLY OF SKIN
12
: 
 The nerve supply of the skin consists of a motor sympathetic portion derived 
from the sympathetic ganglia.Sensory spinal portion arising from the dorsal root 
ganglia. 
PHYSIOLOGY OF SKIN
13
: 
 The skin performs a multiple of functions, though the primary function of skin 
is the protection of organs, it has many other important functions. 
                   These are 
1. Protective function 
2. Sensory function 
3. Storage function 
4. Synthetic function 
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5. Regulation of body temperature 
6. Regulation of water and electrolyte balance 
7. Excretory function 
8. Absorptive function 
9. Secretary function 
10. Gaseous exchange 
 
1. PROTECTIVE FUNCTION: 
                  Skin forms the covering of all organs of the body and protects these organs 
from the     following factors:     
i. Bacteria and toxic substances 
ii. Mechanical flow 
iii. Ultraviolet rays 
 
2. SENSORY FUNCTION: 
 Skin is considered as the largest sense organs in the body. It has many nerve 
endings, which form the specialized cutaneous receptors. These receptors are 
stimulated by the sensations of touch, pain, pressure or temperature sensation and 
convey these sensations to the brain via afferent nerves. 
 
3. STORAGE FUNCTION: 
 Skin stores fat, waters, chlorides and sugar. It can also store blood by the 
dilatation of  the cutaneous blood vessels.      
4. SYNTHETIC FUNCTION:  
 Vitamin D3 is synthesized in skin by the action of ultraviolet rays on cholesterol. 
5. REGULATION OF BODY TEMPERATURE: 
  Skin plays an important role in the regulation of body temperature. Excess 
heat is lost from body through skin by radiation, conduction and evaporation. 
6. REGULATION OF WATER AND ELECTROLYTE BALANCE: 
 Skin regulates water balance and electrolyte balance by excreting water and 
salts through sweat. 
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7. EXCRETORY FUNCTION: 
 Skin can excrete small quantities of waste materials like urea, salts and fatty 
substances. 
8. ABSORPTIVE FUNCTION: 
            Skin can absorb the fat soluble substances and some ointments. 
9. SECRETORY FUNCTION: 
 Skin regulates sweat through sweat glands and sebum through sebaceous 
glands. Sebum keeps the skin smooth and moist. 
10. GASEOUS EXCHANGE: 
A small amount of gaseous exchange through the skin. 
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PSORIASIS 
DEFINITION 
 The word psoriasis is derived from the Greek word “PSORA” meaning 
“ITCH” or“RASH”. The name psoriasis was given by the Viennese dermatologist 
Von Hebra. 
 Psoriasis is a common, non-contagious and chronic skin disease characterized 
by well defined slightly raised, dry erythematous macules with silvery Scales, and 
typical extensor distribution
11
. 
 
 
 
 
  
 
 
 
 It commonly causes red scaly patches to appear on the skin. The scaly patches 
caused by psoriasis, called plaques, are areas of inflammation and excessive skin 
production. Skin rapidly accumulates at these sites and takes a silvery-white 
appearance. Plaques frequently occur on the skin of the elbows and knees, but can 
affect any area including the scalp and genitals.  
 Psoriasis is an inflammatory skin disease in which skin cells replicate at an 
extremely rapid rate. New skin cells are produced about eight times faster than 
normal--over several days instead of a month--but the rate at which old cells slough 
off is unchanged. This causes cells to build up on the skin's surface, forming thick 
patches, or plaques, of red sores (lesions) covered with flaky, silvery-white dead skin 
cells (scales). 
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EPIDEMIOLOGY
14
: 
PREVALANCE 
 It affects 0.6%-4.8% of people worldwide. 
 Men and women are equally affected. 
 It is pandemic in temperate climate. 
 First peak of onset between 20-30 yrs.  
 Second peak of onset between 50-60 yrs. 
 1,50,000-2,60,000 new cases  of psoriasis are diagnosed each year. 
 About 400 people die from complications caused by psoriasis every year. 
 About 11% patients have psoriatic arthritis. 
 Plaque type is most common in 80% of psoriasis patients.   
AETIOLOGY
11
:  
1. The exact cause is unknown- Autoimmune Disease 
2. Stress 
3. Hormonal imbalance 
4. Septic focus 
5. Allergy 
6. Anxiety states 
7. Lowered response of the cyclic AMP system to prostaglandin E1 in 
epidermis 
8. Mental trauma 
9. Fever 
10. Digestive upsets 
11. Physical injury: 
Scratches 
Surgical incisions and injuries 
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12.  Infection: 
β - Hemolytic streptococcal infection- precipitates guttate 
lesions. 
HIV infection-Explosive psoriasis. 
13. Herido familial and Genetic factors: 
Increased in familial cases 
Increased association of HLA- CW6 20 times increased risk 
with early onset of psoriasis 
 
PATHOGENESIS OF PSORIASIS:  
          Psoriasis appears to be largely a disorder of keratinization 
↓ 
The basic defect is rapid replacement of epidermis in psoriatic lesion.  
3 to 4days instead of 28 days in normal skin. 
↓ 
There are marked vascular changes in upper dermis in the form of Recently the 
presence of abnormal neural cells has been demonstrated in Psoriatic plaques.  
 
 
 
 
 
 
 
 
 Psoriasis was long considered either a disorder of keratinocytes growth or 
a chronic inflammation. 
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 Advancement in immunologic techniques and in genetic analyses has 
resulted in a reappraisal of the pathophysiology involved. 
 Psoriasis consider as an organ specific autoimmune disease that is 
triggered by an activated cellular immune system and it similar to other 
immune mediated disease. 
 The definition of autoimmune disease as “a clinical syndrome caused by 
the activation of T cells and B cells, or both, in the absence of an 
ongoing infection or other discernable cause”  
 Pathogenesis of psoriasis still poses a challenge to the scientific 
community to once and for all, establish how and why it occurs and 
consequently to develop the magic drug to treat it.   
 Psoriasis is an immunological disease, characterized by interplay of 
I. Immunological factors. 
II. Cellular components. 
III. Signaling molecules. 
IV. Biochemical changes. 
V. Histological changes. 
 These are plays major role in pathogenesis. 
I. IMMUNOLOGICAL F ACTORS IN PSORIASIS15:  
Both innate or acquired immune changes are thought be responsible for the                                           
Development of psoriatic plaques 
↓ 
Different types of helper T subsets, dendritic cells, plasmacytoid dendritic cells as 
well as Langherhans cells have been found to play a role in psoriasis. 
↓ 
T cells plays important role in psoriasis 
↓ 
Autoimmunity as a major factor in pathogenesis 
↓ 
               The presence of T cells in the inflammatory infiltrate in psoriatic plaque 
obviously  Indicated in immune mediated or an autoimmune basis for the                                                   
Pathogenesis of psoriasis. 
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II. CELLULAR COMPONENTS IN PATHOGENESIS OF PSORIASIS:   
Cellular components are 
a) T cells 
b) Keratinocytes 
c) Langherhans   
A. T CELLS: 
 T cells play a key role, with the epidermal T cells being CD8+ & 
Dermal cells being CD4+. 
 These cells include memory T cells, natural killer cells T cells& 
Th17& Th22. 
 Th17& Th22 cells which are subsets of CD4+ cells are now 
considered important in pathogenesis of the psoriatic plaque. 
 They are stimulated by IL-23 & respectively produce IL-17& IL-
22 which mediate dermal inflammation and epidermal hyperplasia. 
B. KERATINOCYTES: 
 Keratinocytes cells express transcription factor STAT- 3, which 
may be pathogenic. 
C. LANGERHANS CELLS: 
 Langherhans cellssecrete cytokines, which are mitogenic and 
chemotatic. 
III. SIGNALLING MOLECULES IN PATHOGENESIS OF 
PSORIASIS: 
 Include cytokines growth factors like interleukins, Chemokines, 
Interferon’s and their respective receptors. 
 Characterized by up regulation of Th1 cytokines and reduction of 
anti inflammatory cytokines IL-10. 
 Other important molecules include TNF-α, IL-15, IL-17, IL-22 and 
IL-23 
IV. BIOCHEMICAL CHANGES INPATHOGENESIS OF 
PSORIASIS: 
 Cyclic nucleotide increased levels in cGMP or decreased levels of 
cAMP.  
 Arachidonic acid level is increased and it metabolites. 
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 Polyamines also increased in levels. 
 PROTEINASE: increased in levels of plasminogen activator and 
their inhibitors. 
 Calmodulin also increased in levels. 
V. HISTOLOGICAL CHANGES INPATHOGENESIS OF 
PSORIASIS: 
 Epidermal changes is increased epidermal proliferation in two 
ways  
 One is increased growth fraction from normal of 30 to 100% in 
psoriasis. 
 2nd is shortened epidermal turn over time from normal of 60 to10 
days in psoriasis. 
 Important changes seen in dermal layer. 
 Include dilated and tortuous capillary loops and proliferation of 
fibroblasts. 
 Secondary lichenification present 
 Scalp is involved almost all cases 
 No matting of hair 
MOST COMMON SITES
11
: 
AREAS COMMONLY AFFECTED: 
 Scalp 
 Back of elbows 
 Front of knees and legs 
 Lower part of the back of the trunk 
MAY ALSO BE AFFECTED: 
 Nail 
 Sole 
 Palm 
RARELY AFFECTED: 
 Mucus membrane 
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CLINICAL FEATURS OF PSORIASIS
11
:   
 Typical distribution is extensor 
 Lesions are bilaterally symmetrical 
  Typical coin shaped lesion 
 Big plaques of the size of palm of the hand 
 The lesions are slightly raised above the surface of skin 
 Absence of itching 
 But itching present in tropical countries 
 Slight or moderate purities present 
 Secondary psychogenic stress present 
 
IMPORTANT SIGNS OF PSORIASIS
15
: 
1. Candle greeze sign. 
2. Auspitz sign. 
3. Koebner’s phenomenon. 
 
1. CANDLE GREEZE SIGN( Tache de bouge) : 
Psoriatic lesion is scratched with the point of a dissecting forceps a candle 
greeze like scale can be repeatedly produced even from the non scaling lesions 
this is called candle greeze sign (Tache de bouge) 
2. AUSPITZ  SIGN: 
The complete removal of scale produces pin point bleeding. There are 3 steps 
to this test: 
STEP 1: Gently scrape lesion with a glass slide. This accentuates the silvery scales 
(GRATTAGE TEST POSITIVE) scrape off all the scales. 
STEP 2: As you continue to scrape the lesion, a glistening, white adherent 
membrane(BERKLEY’S MEMBRANE) appears. 
STEP 3: On removing the membrane, punctuate bleeding points become visible, this 
is positive AUSPITZ SIGN. 
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3. KOBNER’S PHENOMENON: 
Psoriatic lesions may develop along the scratch lines in the active phase this is called 
Koebner’s phenomenon. 
TYPES OF PSORIASIS
11 
: 
 Plaque Psoriasis 
 Nail Psoriasis 
 Guttate Psoriasis  
 Inverse Psoriasis 
 Pustular Psoriasis 
 Erythrodermic Psoriasis 
 Psoriatic Arthritis 
 
PLAQUE PSORIASIS:  
 The most common form, palque psoriasis causes dry, raised,red skin 
lesions(plaque) covered with silvery scales. The plaques might be few or itchy or 
painful and there may be few or many. They can occur anywhere on your body, 
including your genitals and the soft tissue your mouth. 
 
NAIL PSORIASIS:  
 Psoriasis can affect fingernails and toenails, causing pitting, abnormal nail 
growth and discoloration. Psoriatic nails might loosen and separate from the nail bed. 
Severe cases may causes the nail to crumble. 
 
GUTTATE PSORIASIS:  
 This type primarily affects young adults and children. Its usually triggered by 
a bacterial infection such as strep throat. Its marked by small, water-drop-shaped, 
scaling lesions on your trunk, arms, leg and scalp. You may have a single outbreak 
that goes away on its own, or you may have repeated episodes. 
 
INVERSE PSORIASIS: 
 This mainly affects the skin in the armpits, in the groin, under the breasts and 
around the genitals. Inverse psoriasis causes smooth patches of red, inflamed skin that 
worsen with friction and sweating. Fungal infection may trigger this type of psoriasis. 
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PUSTULAR PSORIASIS: 
 This uncommon form of psoriasis can occur in wide spread 
patches(generalized pustular psoriasis) or in smaller areas on your hands, feet or 
fingertips. 
 It generally develops quickly,with pus-filled blisters appearing just hours after 
your skin becomes red and tender. The blisters may come and go frequently. 
Generalized pustular psoriasis can also cause fever, chills, severe itching and diarrhea. 
 
ERYTHRODERMIC PSORIASIS:  
 The least common type of psoriasis, erythrodermic psoriasis can cover your 
entire body with a red, peeling rash that can itch or burn intensely.  
 
PSORIATIC ARTHRITIS:  
 In addition to inflamed, scaly skin, psoriatic arthritis causes swollen, painful 
joints that are typical of arthritis. Sometimes the joint symptoms are the first or only 
manifestation of psoriasis or at times only nail changes are seen. Symptoms range 
from mild to severe and psoriatic arthritis can affects any joint. Although the disease 
usually is not as crippling as other forms of arthritis, it can cause stiffness and 
progressive joint damage that in the most serious cases may lead to permanent 
deformity. 
 
COMPLICATIONS
11
:  
Psoriatic arthritis:  
                 This complication of psoriasis can cause joint damage and a loss of 
function in some joints, which can be debilitating. 
Eye conditions:  
 Certain eye disorders-such as conjunctivitis, blepharitis and uveitis-are more 
common in people with psoriasis. 
 
Obesity: 
 People with psoriasis especially those with more severe disease, are more 
likely to be obese. Its not clear hoe these diseases are linked, however. The 
inflammation linked to obesity may play a role in the development of psoriasis. Or it 
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may be that people with psoriasis are more likely to gain weight, possibly because 
they are less active because of there psoriasis. 
 
Type 2 diabetes:  
 The risk of type 2 diabetes raises in people with psoriasis. The more severe the 
psoriasis, the greater the likelihood of type two diabetes. 
 
High blood pressure:  
 The odds of having high blood pressure are higher for people with psoriasis.  
 
Cardiovascular disease:  
 For people with psoriasis, the risk of cardiovascular disease is twice as high as 
it is for those without the disease. Psoriasis and some treatments also increase the risk 
of irregular heartbeat, stroke, high cholesterol and atherosclerosis. 
 
Metabolic syndrome:  
 This cluster of conditions-including high blood pressure, elevated insulin 
levels and abnormal cholesterol levels-increases your risk of heart disease. 
 
Other autoimmune diseases:  
 Celiac disease, sclerosis and the inflammatory bowel disease called crohn’s 
disease are more likely to strike people with psoriasis. 
 
Parkinson’s disease:  
 This chronic neurological condion in more likely to occur in people with 
psoriasis. 
 
Kidney disease:  
 Moderate to severe psoriasis has been linked to a higher risk of kidney disease. 
 
Emotional problems:  
 Psoriasis can also affect your quality of life. Psoriasis is associated with low 
self-esteem and depressions. You may also withdraw socially.  
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DIFFERENTIAL DIAGNOSIS OF PSORIASIS
15
:                
 
S.NO 
 
TYPE OF RASH 
 
DISTRIBUTION 
 
MORPHOLOGY 
1 ECZEMA Face/ Flexures Poorly defined Erythema 
and scaling lichenification 
2 SEBORRHOEIC 
DERMATITIS 
Scalp, axilla, sterna 
region 
Scalp patches are diffuse, 
ill-defined and moist, hair is 
matted with crust. 
3 PITYRIASIS 
ROSEA 
“Fire tree pattern” on 
torso 
Well defined erythematous 
papules and plaques with 
scales 
4 DRUG 
ERUPTION 
Wide spread Maculopapular 
erythematous scaly areas 
which merge and are 
followed by exfoliation 
5 PITYRIASIS 
VERSICOLOR 
 
Upper torso and 
upper shoulders 
Hypo and hyper pigmented 
scaly patches 
6 LICHEN 
PLANUS 
Distal limbs, 
especially wrists and 
lower back 
Shiny,flatopped violaceous 
papules with Wickham’s 
striae 
7 TINEA 
CORPORIS 
Asymmetrical, often 
isolated, red scaly 
lesions 
Scalyplaques which expand 
With central healing  
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LAB INVESTIGATION OF PSORIASIS
15
: 
Skin biopsy shows the following as 
EPIDERMAL CHANGES: 
 Parakeratosis 
 Loss of granular layer and regular acanthosis 
 Supra papillary thickening 
 Collection of polymorphs in the epidermis to form spongiform pustule 
of kogoj and Munro’s micro abscess seen in epidermis. 
DERMAL CHANGES: 
 Dilatation and tortuosity of capillary loops in the dermal papillae 
 Lymphocytic infiltrate in the upper dermis is seen. 
HISTOLOGICAL CHANGES: 
 Thinning of supra papillary portion of stratum malpinghii 
 Elongation of ridges 
 Oedema and clubbing of papillae seen in histological study. 
HISTOCHEMICAL CHANGES: 
 Histochemical studies have revealed an increase in both oxidative and 
anaerobic metabolism with increased pentose, glycon, purines, 
sulphydral groups, soluble proteins increased in level. 
 Decreased in activity of dipeptidases. 
 It has been discovered that apparently normal skin of both the 
psoriatics and their relations show these changes in miniature is called 
LATENT PSORIASIS 
RADIOLOGICAL CHANGES: 
 . Simultaneous presence of ankylosis, periosteal new bone formation, 
erosions and osteolytis are strongly suggestive of psoriatic arthritis. 
 
TREATMENT OF PSORIASIS PATIENTS
15
: 
Depending on the type of psoriasis, various therapeutic options are available 
 Topical agents like liquid paraffin, petroleum gel, vegetable oils etc. 
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 Systemic agents like Methotrexate, Acitretin, and Cyclosporine. 
 Corticosteroids mostly in cream base. 
 Photochemotherphy and phototherapy in PUVA methods. 
 Biological response modifiers used in treatment of psoriasis. 
 
 
DIET FOR PSORIASIS PATIENTS: 
TO TAKE: 
1. All green leafy vegetables. 
2. Low consumption of animal fats and the quantity of food. 
3. High protein diet 
4. Fish and sea foods 
5. Carrot 
6. Tomatoes 
7. Grains. 
TO AVOID: 
1. Oil foods. 
2. High fat diet 
3. Alcohol 
4. Junk foods 
5. Red meat 
6. Dairy products 
7. Night shade vegetables 
8. Citrus fruits 
9. Gluten protein in diet 
10. Condiments. 
 
PROGNOSIS
11
: 
 A permanent cure is not yet known 
 Individual attacks can, almost always controlled satisfactorily 
 Disease non infectious 
 The disease does not leave scar 
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 Flexural, erythrodermic and pustular psoriasis take longer to 
heal than the typical variety 
 The palmar and nail lesions are rather resistant to treatment. 
 Patient suffer from the disease on and off throughout their 
lives. 
 Complications in psoriasis are infrequent. 
 
MANAGEMENT
11
: 
 The general health of the patient should be maintained. 
 The patient’s life should be regulated so that no undue stress 
affects either body (or) mind. 
 A moderate, warm climate, frequent sunbaths before the onset of 
the winter, and visits to sulphur springs, all of which are useful 
in bringing down the relapse rate. 
 Natural sulphur baths should be taken during the holidays, 
especially in the winter season. 
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                                                DRUG REVIEW 
3.3. INTERNAL MEDICINE: SWARNA PUSHPA RASA CHENDHURUM 
INGREDIENTS: 
 Gandhagam (Sulphur)  
 Velvangam (Stannum)   
 Navacharam (Ammonichloridum)      
 Rasam (Hydragyrum)   
 Kalyanapoosanikai (Benincasahispida) 
 
 GANDHAGAM        RASAM 
 
 
 
 
 
 
 
 
 NAVACHARAM     VELVANGAM
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GANTHAGAM(SULPHUR): 
                        16: 
“                                
                       –        
                           
                    .” 
INTRODUCTION
17
: 
 Sulphur forms an essential constituent of many natural products of plant and 
animal origin e.g., Garlic, mustard, eggs, hair etc. 
 It also occurs as hydrogen sulphide in spring waters, coal gas, sewage etc. 
GENERAL PROPERTIES: 
IUPAC NAME            :  Sulphur 
SYMPOL                    :  S 
ATOMIC NO              :   16 
PHASE                         :   Ore 
MELTING POINT     :  388.36
0
C (114.00K) 
BOILING POINT       :  717.8
0
C (444.6K) 
 
PROPERTIES OF SULPHUR: 
 Sulphur is a yellow solid with no state and odour. 
 It is freely soluble in carbon di sulfide but insoluble in water and only 
sparingly soluble in alcohol and ether. 
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 Sulphurvapors are poisonous to had bacteria and fungi but not for animals or 
human beings. 
 It combines directly with carbon, phosphorus, arsenic and many of the 
metals at high temperatures, giving the corresponding sulphides. 
 As disinfectant it is used to destroy had bacteria, Fungi in household purpose 
USES: 
 This is considered to useful in the treatment of 18 types of skin 
diseases. 
RASAM (HYDRAGYRUM)
16
: 
          : 
“                           
                   –      
                       
            .” 
INTRODUCTION
17
: 
 Mercury is obtained from ores in countries like spain, china & japan. 
 It is separated from its cinnabar. 
 Mercury of commercial grade available in shops is in impure from, 
found mixed with lead, tin, sand, dust etc. 
 The mercury obtained from cinnabar is considered as pure and suitable 
for medicinal purposes. 
GENERAL PROPERTIES: 
 IUPAC NAME  :  Hydragyram 
 SYMPOL             :  Hg 
 ATOMIC NO :   80 
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 PHASE :   Liquid 
 MELTING POINT : 38.9
0
C (234.321O K) 
 BOILING POINT :  356.6
0
C (629. 88 K) 
PROPERTIES OF RASAM: 
 It purifies blood 
 Kills the micro-organism and cures the ulcers 
 It cures the disease of internal and external organs of the body 
 It strengthens the nerve plexus 
 It develops wisdom through concentration of mind 
 It prevents the senility and increases the life span 
USES: 
 Mercury vapor lamps are used as a source of ultraviolet light. 
 Mercury and its compounds are extensively used in medicine. 
 Proper use of mercury medicine, cures the diseases of eyes, throbbing 
pain, 8 types of ulcers, chronic ulcer, leprosy and kuttam diseases. 
 
VELVANGAM (STANNUM)
16
: 
     க        : 
“                        
                   –       
                         
              .” 
 
INTRODUCTION
17
: 
 Velvangam is also known as Velleeyam, Vengalam, Kudiyam and 
Thavalavangam 
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 There are two types of velvangam. One is kuragam which is white in 
colour has the quantities of thickness, soft, oily, coolness, easily 
melting and soundless etc.. 
 Another one is misaragam has the mixed colour of white and black. 
PROPERTIES OF VELVANGAM: 
 Stannum has got antiseptic and demulcent properties. 
 It is astringent taste 
 It is hot in potency 
USES: 
 It has also got the property of reducing edema 
 Stannum is used for the treatment of eczema, certain skin diseases 
NAVACHARAM (AMMONIUM CHLORIDE)
16
: 
                  : 
 
“                          
                        –      
                       
              ”. 
 
INTRODUCTION
17
: 
 Other names of navacharam is istigai, salligai, sooligai and padu 
 This is available in small quantities in brick stone furnace. 
 This is also obtained by sublimation of coal, salt and dung ashes of 
camel. 
 It has no smell. 
 Solid in state. 
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 Fibre in nature and so it is hard to powder. 
 It is dissoluble in water and alcohol. 
GENERAL PROPERTIES: 
 IUPAC NAME             : Ammonium chloride 
 SYMPOL   :  NH4CL 
 PHASE                :   powder form 
 MELTING POINT     :  338
0
C(640
0
F ; 611 K) 
 BOILING POINT         :  520
0
C(968
0
F ;793 K) 
PROPERTIES OF NAVACHARAM: 
 In a small doses given for a long period, improves the body strength 
 It is also having stimulant and diaphoretic activity. 
USES: 
 It has also used for the bad odour in the skin 
 This is also effective for scabies, eczema, Herpes zoster and Hansen’s 
diseases. 
KALIYANA PUSHNIK-KAY
 
க         க         
20 
“                              
                 –       
                             
            ”. 
 
BOTANICAL NAME: Benincasahispida 
FAMILY NAME:  cucurbitaceae 
 OTHER NAMES: kushmanda, 
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CHEMICAL CONSTITUENTS: volatile oils,glycosides  
 PHARMACOLOGICAL ACTIVITY: antioxidant activity 
USES: It cures wounds. 
3.4 EXTERNAL MEDICINE:VETTIVER THYLAM  
INGREDIENTS: 
 Vettiver (Vetiveriazizanioides)   
 Athimathuram (Glycyrrhizaglabra)  
 Karunseeragam (Nigella sativa)   
 Devadharam (Cedrusdeodara)   
 Kadukkai (Terminaliachebulae)   
 Gingilley oil (Sesamumindicum)  
 
 
 
  Vettiver     Devadharam 
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  Athimathuram     Kadukkai  
 
 
 
 
 
  Karunseeragam     Gingilee 
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VETTIVER 
              
20 
:
 
 
“                           
                          
                              
                              ”. 
 
BOTANICAL NAME: Vetiveriazizanioides 
FAMILY NAME:  poaceae 
OTHER NAMES: khaskhas grass, kuskus grass, vetiver 
PHARMACOLOGICAL ACTIVITY:It has antioxidantactivity 
USES: It is very effective in preventing acne. 
ATHIMATHURAM 
             
20
: 
“                      
                           
                       
                      ”. 
 
BOTANICAL NAME: Glycyrrhizaglabra  
FAMILY NAME:  fabaceae 
OTHER NAMES: liquorice, licorice 
CHEMICAL CONSTITUENTS: glycyrrhizin,glycyrrhizinic acid  
 PHARMACOLOGICAL ACTIVITY: It has antimicrobial and antioxidant activity 
 USES: It can be used to fight dermatitis, eczema and psoriasis. 
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KARUNSEERAGAM 
க    க        
20
: 
                        
                 –        
                             
               . 
 BOTANICAL NAME: Nigella sativa  
FAMILY NAME:  Rananculaceae 
OTHER NAMES: Black-caraway, black-cumin, fennel-flower,kalongi 
CHEMICAL CONSTITUENTS: Thymoquinone, thymol, carvacrol 
ACTIONS:Anthelmintic, parasiticide 
 PHARMACOLOGICAL ACTIVITY: It has Anticancer activity and 
anti-proliferant property 
USES:  eczema, scabies 
DEVADHARAM 
             
20
: 
“                       
               –         
whkaQ;R thrtyp az;zhjk; fk;gf; fhw; 
                 ”. 
 
BOTANICAL NAME: Cedrusdeodara  
FAMILY NAME:  Pinaceae 
OTHER NAMES: deodar cedar, deodar 
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CHEMICAL CONSTITUENTS: 9- hydroxyl-dodecanoic acid, ethyl 
laurate 
 PHARMACOLOGICAL ACTIVITY: It has Anti-bacterial Activity. 
 
USES: It cures eczema and psoriasis. 
KADUKKAI – க  க         20 
                      
                –          
                        
                  
BOTANICAL NAME: Terminaliachebulae 
FAMILY NAME:  Comberetaceae 
OTHER NAMES: Chebulicmyrobalan 
CHEMICAL CONSTITUENTS: Ellagic acid, Chebulinic acid 
 PHARMACOLOGICAL ACTIVITY: It has Anti-proliferantproperty 
,It has anti-oxidant property 
 
USES:  It cures Kuttam 
GINGILEE OIL 
எ              20: 
“                             
                  –           
                                
                         .” 
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BOTANICAL NAME: Sesamumindicum 
FAMILY NAME:  Pedaliaceae 
OTHER NAMES: Sesame, Sesamum 
PHARMACOLOGICAL ACTIVITY: Anti-oxidant activity 
CHEMICAL CONSTITUENTS: Sesamin,Sesamolin, Linoleic Acid, 
Oleic Acid, Palmitic Acid 
USES: Oil used for cooling effect, External application for Wounds and scabies. 
  
 
3.5 PRANAYAMAM 
 
Pranayamam mainly act via down regulating the HPA axis (Hypothalamic 
Pituitary Adrenal axis) that trigger as a response to a physical or psychological 
demand, leading to release of cortisol and catecolamines (epinephrine, nor-
epinephrine). Repeated firing of the HPA Axis can lead to the deregulation of the 
system and ultimately diseases such as obesity, diabetes mellitus, autoimmune 
diseases, cardiovascular disorder. 
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PRANAYAMAM STEPS: 
 Close your eyes 
 Close the right nostril with the right thumb 
 Inhale slowly through the left nostril 
 Remove your thumb from your right nostril 
 Use your ring and middle finger to close your left nostril 
 Exhale slowly and completely with the right nostril 
 
BENEFITS OF PRANAYAMAM: 
 With this pranayama you will instantly experience peace and blissfulness 
 It is said in the yoga science this pranayama cleanses, 72,000 Nadis or 
channels in the body 
 It helps purify the blood and the respiratory system 
 The deeper breathing enriches the blood with oxygen 
 
S 
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4.  MATERIALS AND METHODS 
SELECTION OF DRUGS:  
I have selected the trial drugs “SwarnaPushpa Rasa Chendhuram” (Int) for 
this study from Classical Siddha literature SikichaRathinaDeepam- 
KannusamyPillai Page No:240, “VettiverThylam” (Ext) from 
AathmaracchamirthaVaithiyaSaarasangragam Part-1 Page No:527 and 
“Pranayamam”. 
 
 The raw drugs were procured from the raw drug shop R. N. Rajan and Co, 
Chennai. After proper authentication by the Pharmacognosist, Govt Siddha Medical 
College, Arumbakkam, Chennai, the preparation was made. My CTRI No is 
REF/2017/04/014066. 
 INTERNAL DRUG: SWARNA PUSHPA RASA CHENDHURAM  
INGREDIENTS: 
 Purified Rasam (Hydragyrum)   
 Purified Gandhagam (Sulphur)   
 Purified Velvangam (Stannum)   
 Purified Navacharam (Ammonichloridum)        
 Kalyanapoosanikai(Benincasahispida) 
4.1 PURIFICATION OF THE DRUG INTERNAL SWARNA PUSHPA RASA 
CHENDHURAM (SPRC)
16
: 
PRECAUTIONS CARRIED OUT DURING PURIFICATION TECHNIQUE: 
1.It was carried out in open space. 
2. Mask was weared. 
3. Before flaming care has been taken to wipe out the side of all the instruments. 
4. Avoid to touching the drug while washing. 
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PURIFICATION OF SULPHUR (GANDHAGAM) 
MELTING AND POURED INTO LIQUID METHOD (URUKI SAITHAL 
MURAI) 
 
                MELTING                                                          POURING 
 
 
PURIFIED  GANDHAGAM 
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MATERIALS USED:   
Gandhagam -100g, Milk-1liter. 
EQUIPMENTS USED:   
Iron spoon, mud pot, stove, tissue paper.  
PROCEDURE:   
Gandhagam is placed in an iron spoon, the spoon is heated till the gandhagam 
melts. Then it is poured in milk. This is repeated for 2 times. After that gandhagam is 
taken out and washed with cool water and allowed it to dry.  
PURIFICATION OF MERCURY (RASAM): 
 
        Trituration of Hg with Turmeric                                   Added Brick powder 
 
                                          After purification of mercury 
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MATERIALS USED:   
Mercury-100g, Brick powder, Turmeric powder, Acalyphaindica Leaf juice 
 
EQUIPMENTS USED:   
Stove, mud plate 
 
PROCEDURE:   
100 g of mercury was triturated with brick powder and turmeric powder and 
washed with water. Then the mercury was boiled with acalypha leaf juice for about 30 
minutes.  
 
PURIFICATION OF VELVANGAM (STANNUM): 
 
MATERIALS USED:   
 Velvangam – 100g, vitexnegundo juice, turmeric   
 
EQUIPMENTS USED:   
 Stove, iron spoon 
 
PROCEDURE:   
Place velvangam in iron spoon and heated. The melted velvangam is poured 
into vitexnegundo juice and turmeric(Curcuma longa). Repeat it for 2 times. 
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PURIFICATION OF NAVACHARAM (AMMONICHLORIDUM) : 
 
 
  Navacharam   After purification of Navacharam 
 
MATERIALS USED:   
 Navacharam – 100g 
EQUIPMENTS USED: 
 Hot water, Vessel 
PROCEDURE:   
Mix it with hot water and filtered. After self cooling keep it in sunlight. Now 
the salt settles down at the bottom of the vessel. 
 
4.2 STANDARD OPERATING PROCEDURE FOR SWARNA PUSHPA RASA 
CHENDHURAM (INT)
18
: 
 
P.Velvangam is to be melted andslightly cool. Added with P.Rasamand 
grinded well. P. Navacharam and P. Gandhagam are added and grinded with lemon 
juice for 12 hrs.Make it into poultices (Villai), dry it and keep inside the small mud 
pot. Place small mud plate over small mud pot and sealed by 7 layers of mud pasted 
cloth. Next the big mud pot is filled with sand.Keep small mud pot inside the big mud 
pot.Place the suitable mud plate over the big mud pot and sealed it with 7 layers of 
mud pasted cloth.The big mud pot is ignited for 12 hrs.Afterself cooling the seal is 
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open.The  product  obtained  is again grinded with Benincasahispida  juice for 3 hrs 
and dried in moon shade. The end product is powdered, weighed  and preserved in an 
air tight container. 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
     IGNITED CHENDHURAM        END PRODUCT OF CHENDHURAM
     
 
DOSAGE: 130mg, twice daily 
VEHICLE: Thaen 
DURATION: 48 Days 
INDICATIONS: Kuttam, Megaranam, Pun puraigal. 
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4.3. EXTERNAL DRUG: VETTIVER THAILAM 
 
 INGREDIENTS: 
 Vettiver (Vetiveriazizanioides)   
 Athimathuram (Glycyrrhizaglabra)  
 Karunseeragam (Nigella sativa)   
 Devadharam (Cedrusdeodara)   
 Kadukkai (Terminaliachebulae)   
 Gingilee oil (Sesamumindicum)  
 Water  
 
 
 
 
  Vettiver     Devadharam 
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 Athimathuram     Kadukkai 
    
 
  Karunseeragam     Gingilee oil 
 
PROCEDURE
19
: 
 Water is boiled and vettiver is added to it and made into decoction. All the 
other ingredients are grinded with decoction and made into paste. Gingilley oil, 
decoction and the grinded paste are mixed together and heated until it turns into waxy 
consistency. 
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                            ADD WATER     DECOCTION 
 
 
 
 
 
 
 
 
                       GINGELLY OIL                    MIXED GRINDED RAW DRUGS 
 
 
 
 
 
 
 
      VETTIVER THYLAM   
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INDICATIONS: 
Kuttam, Peenisam, Mandaisoolai, Puraneerkovai, Kanpugaichal, 
Kadhumandham, Ilaippu, Thadhunastam, Irumal, Thegakandhal. 
 
4.4. PRANAYAMAM: 
PROCEDURE: 
 First, sit relax with closed eyes in such a way that head, neck and spine 
straight. 
 Face smiling and shoulder relaxed. 
 Concentrate on your breathing. 
 Make Naasimuthirai in right hand and Chin muthirai in left hand.  
 Inhale through right nostril, close your right nostril, exhale slowly and 
completely through left nostril. 
 Inhale through left nostril, close your left nostril, exhale slowly and 
completely through right nostril. This is one round. 
 It is recommended 15 rounds for the patients every day in early morning and 
evening with empty stomach. 
STANDARDIZATION OF SPRC: 
Standardization of herbal formulation is essential to access the quality of drugs for 
therapeutic value. Standardization of SPRC based on organoleptic characters, physical 
characteristics and physicochemical properties.   
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4.4. STANDARDIZATION PARAMETERS:  
4.4.1. TRADITIONAL WAY OF TESTING CHENDHURAM  
1. Colour:  
Red in colour without any shiny appearance 
2. Taste and odour:  
Tasteless and odourless 
3. Luster  
Did not regain luster on heating again at same temperature  
4. Floating on water  
Sample floats on water. Did not immediately immersed in water  
5. Finger furrows test.  
Impinged in the papillary ridges when the sample rubbed in between Index 
finger and thumb   
4.4.2. PHYSICOCHEMICAL ANALYSIS: 
DETERMINATION OF PH  
1% solution of PMC was prepared in distilled water and pH was determined  
by using pH meter Systronics digital pH meter.  
DETERMINATION OF MOISTURE CONTENT  
Moisture content was determined by LOD (Loss on Drying) method. 3gm 
VPM was taken and kept in oven at 105 0c till a constant weight was obtained.  
Amount of moisture present in the sample was calculated as referred to the air 
dried drug.  
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TOTAL ASH   
A weighed amount of the powder was taken in a silica crucible previously 
ignited, cooled and weighed. It was incinerated using incinerator by gradually 
increasing the heat not exceeding dull red heat (450°C) until free from carbon, cooled 
and weighed. The percentage of ash was calculated with reference to air-dried 
drug.The procedure was repeated to get constant weight.      
WATER SOLUBLE ASH  
The total ash was boiled with 25 ml water and filtered through ash less filter 
paper (Whatmann 4.1). It was followed by washing with hot water. The filter paper 
was dried and ignited in a silica crucible, cooled and the water insoluble ash was 
weighed. The water-soluble ash was calculated by subtracting the water insoluble ash 
from the total ash.    
ACID INSOLUBLE ASH  
The total ash obtained was boiled for 5 minutes with 25 ml of dilute 
hydrochloric acid (10% w/v) and filter through ash less filter paper (Whatmann No.1). 
The filter paper was ignited in a silica crucible, cooled and weighed.  
DETERMINATION OF ALCOHOL SOLUBLE EXTRACTIVE  
The air dried drug was finely grounded, added with 100 ml of ethanol of 
specified strength in a closed flask for twenty-four hours, shaken frequently during 
the course of six hours and allowed to stand for eighteen hours. Then the mixture was 
filtered rapidly taking precautions against loss of solvent, 25 ml of the filtrate was 
evaporated to dryness in a tarred flat bottomed shallow dish, and dried at 105º to 
constant weight. The percentage of alcohol-soluble extractive with reference to the 
air-dried drug was estimated.   
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4.4.3. HEAVY METAL ANALYSIS 
 
Heavy metal Procedure  Results  
Mercury  1. Add 5ml of hydrochloric 
acid  to little substance, 
precipitate appears 
2.  Then  boil the precipitate 
with water. It does not 
dissolves add sodium 
hydroxide solution .heat it 
and fillter 
No  Black precipitation 
appears 
Lead  1.add 2ml of potassium chormate 
to salt solution.  
No yellow precipitate 
appears 
 
Arsenic  To 10 drops of solution. Add 6ml 
NH3  until neutral.make the 
solution acidic b adding one or 
more drops of 6 M HCL. Add 1 
ml of thioacetamide and stir well. 
Heat the test tube in the boiling 
water bath for 5 minutes  
No  red orange precipitate  
Or 
Yellow or brown 
precipitates appears 
Cadmiam  add 2ml of solution, add 1 ml 
NaOH, add  1ml of distal water 
and add  1 ml of Hcl  
No Yellow  precipitates 
appears
 
Chromium  To 10 drops of solution, add 1ml 
of 3% H2O2 then add 6M NaOH 
dropwise untill the solution is 
basic. Heat in a boiling water 
bathh for a few minutes 
No  yellow solution of 
CrO4
2 
form 
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4.5. TOXICOLOGICAL STUDY 
4.5.1. ACUTE ORAL TOXICITY STUDY OF SWARNA PUSHPA 
RASA CHENDHURAM 
(OECD GUIDELINE – 423)   
                    The experimental protocol was permitted by the Institutional Animal 
Ethical Committee (IAEC) under CPCSEA, approval no: IAEC/XL 
VIII/28/CLBMCP/2016 
 
Introduction: 
 The acute toxic class method is a stepwise procedure with the use of 3 animals 
of a single sex per step. 
 Depending on the mortality and/or the moribund status of the animals, on 
average 2-4 steps may be necessary to allow judgement on the acute toxicity 
of the test substance.  
 This procedure is reproducible, uses very few animals and is able to rank 
substances in a similar manner to the other acute toxicity testing methods.  
 The acute toxic class method is based on biometric evaluations with fixed 
doses, adequately separated to enable a substance to be ranked for 
classification purposes and hazard assessment.  
 In principle, the method is not intended to allow the calculation of a precise 
LD50, but does allow for the determination of defined exposure ranges where 
lethality is expected since death of a proportion of the animals is still the major 
endpoint of this test.  
 The method allows for the determination of an LD50 value only when at least 
two doses result in mortality higher than 0% and lower than 100%.  
 The use of a selection of pre-defined doses, regardless of test substance, with   
classification explicitly tied to number of animals observed in different states 
improves the opportunity for laboratory to laboratory reporting consistency 
and repeatability.  
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Principle of the Test:  
It is the principle of the test that based on a stepwise procedure with the use of 
a minimum number of animals per step, sufficient information is obtained on the 
acute toxicity of the test substance to enable its classification. The substance is 
administered orally to a group of experimental animals at one of the defined doses. 
The substance is tested using a stepwise procedure, each step using three animals of a 
single sex. Absence or presence of compound-related mortality of the animals dosed 
at one step will determine the next step, i.e. 
− no further testing is needed 
− dosing of three additional animals, with the same dose  
− dosing of three additional animals at the next higher or the next lower dose 
level. The method will enable a judgment with respect to classifying the test substance 
to one of a series of toxicity classes. 
 
Methodology: 
Selection of Animal Species  
 The preferred rodent species is the wister rat, although other rodent species 
may be used. Healthy young adult animals are commonly used laboratory strains 
should be employed. Females should be nulliparous and non-pregnant. Each animal, 
at the commencement of its dosing, should be between 6 to 8 weeks old and the 
weight (150-200gm) should fall in an interval within±20 % of the mean weight of any 
previously dosed animals.  
Housing and Feeding Conditions 
 The temperature in the experimental animal room should be 22ºC + 3ºC.  
Although the relative humidity should be at least 30% and preferably not exceed 70% 
other than during room cleaning the aim should be 50-60%. Lighting should be 
artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional 
laboratory diets may be used with an unlimited supply of drinking water. Animals 
may be group-caged by dose, but the number of animals per cage must not interfere 
with clear observations of each animal. 
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Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and 
kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
Test Animals and Test Conditions:  
 Sexually mature Female Wistar albino rats (150-200gm) were obtained from 
TANUVAS, Madhavaram, Chennai. All the animals were kept under standard 
environmental condition (22±3°C).  The animals had free access to water and 
standard pellet diet (Saimeera foods, Bangalore). 
 
Preparation of animals:   
The animals are randomly selected, marked to permit individual identification, and 
kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the 
laboratory conditions 
 
Preparation for Acute Toxicity Studies 
 Rats were deprived of food overnight (but not water 16-18 h) prior to administration 
of the, SWARNA PUSHPA RASA CHENDHURAM. 
The principles of laboratory animal care were followed and the Institutional 
Animal Ethical Committee approved the use of the animals and the study design 
 
IAEC NUMBER: IAEC/XL VIII/28/CLBMCP/2016 
 
Test Substance  : SWARNA PUSHPA RASA CHENDHURAM 
Animal Source  : TANUVAS,Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Female-3+3) 
Age    : 6-8 weeks 
Body Weight on Day 0 : 150-200gm. 
Acclimatization  : Seven days prior to dosing. 
Veterinary examination : Prior and at the end of the acclimatization period. 
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Identification of animals : By cage number, animal number and individual   
                                marking by using Picric acid. 
Numberofanimals               : 3 Female/group,  
Routeofadministration      :   Oral  
 
Diet    : Pellet feed supplied by Saimeera foods Pvt Ltd,  
     Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
       provided with bedding of husk. 
Housing temperature :  between 22ºC +3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour and  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 14 Days 
Administration of Doses:  
 SWARNA PUSHPA RASA CHENDHURAM was suspended in water and 
administered to the groups of wistar albino rats in a single oral dose by gavage using a 
feeding needle. The control group received an equal volume of the vehicle. Animals 
were fasted 12 hours prior to dosing. Following the period of fasting, the animals 
were weighed and then the test substance was administered. Three Female animals are 
used for each group. The dose level of 4mg/kg body weight was administered. After 
the substance has been administered, food was withheld for a further 3-4 hours. The 
principle of laboratory animal care was followed. Observations were made and 
recorded systematically and continuously as per the guideline after substance 
administration. The visual observations included skin changes, mobility, aggressively, 
sensitivity to sound and pain, as well as respiratory movements. Finally, the number 
of survivors was noted after 24 hrs and these animals were then monitored for a 
further 14 days and observations made daily. The toxicological effect was assessed on 
the basis of mortality. 
 
Observations:  
Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the 
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first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be 
removed from the study and humanely killed for animal welfare reasons or are found 
dead. It should be determined by the toxic reactions, time of onset and length of 
recovery period, and may thus be extended when considered necessary. The times at 
which signs of toxicity appear and disappear are important, especially if there is a 
tendency for toxic signs to be delayed. All observations are systematically recorded 
with individual records being maintained for each animal. 
 
Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Attention was directed to observations of 
tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles 
and criteria summarized in the Humane Endpoints Guidance Document taken into 
consideration. Animals found in a moribund condition and animals showing severe 
pain or enduring signs of severe distress was humanly killed. When animals are killed 
for human reasons or found dead, the time of death was recorded. 
 
 Acute oral toxicity study of SWARNA PUSHPA RASA 
CHENDHURAM 
Table 1: Dose finding experiment and its behavioral Signs of acute oral 
Toxicity 
 
Observation done: 
SL 
Group 
CONTROL 
Observation 
Group 
TEST GROUP 
Observation 
1 Body weight Normal Body weight Normally increased 
 
2 Assessments of posture Normal Assessments of posture Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal Signs of Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal Body tone Normal 
5 Lacrimation Normal Lacrimation Absence 
6 Salivation Normal Salivation Absence 
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7 Change in skin color No significant 
color change 
Change in skin color No significant color 
change 
8 Piloerection Normal Piloerection Normal 
9 Defecation Normal 
 
Defecation Normal 
 10 Sensitivity response Normal Sensitivity response Normal 
11 Locomotion Normal Locomotion Normal 
12 Muscle gripness Normal Muscle gripness Normal 
13 Rearing Mild Rearing Mild 
14 Urination Normal Urination Normal 
 
Behaviour: 
 The animals will be observed closely for behaviour in the first four hours 
which  includes abnormal gait, aggressiveness, exophthalmos, ptosis, akinesia, 
catalepsy, convolusion, excitation, head twitches, lacrimation, loss of corneal reflex, 
loss of traction, piloerection  reactivity of touch, salivation, scratching, sedation, 
chewing,  head movements, sniffing, straub, tremor and writhes, diarrhea, leathery, 
sleep and coma.  
 
Body Weight:  
Individual weight of animals was determined before the test substance was 
administered and weights will be recorded at day 1, 7, and 14 of the study. Weight 
changes were calculated and recorded. At the end of the test, surviving animals were 
weighed and humanly killed. 
 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the treated dose 
groups.  
 
Mortality: 
Animals were observed for mortality throughout the entire period. 
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4.5.2. SUB ACUTE TOXICITY 
REPEATED DOSE 28-DAY ORAL TOXICITY (407) STUDY OF 
SWARNA PUSHPA RASA CHENDHURAM 
 
Test Substance  : SWARNA PUSHPA RASA CHENDHURAM 
Animal Source  : TANUVAS, Madhavaram, Chennai.   
Animals   : Wister Albino Rats (Male -24, and Female-24) 
Age    : 6-8 weeks 
Body Weight               : 150-200gm. 
Acclimatization  : Seven days prior to dose. 
Veterinary examination : Prior and at the end of the acclimatization period. 
Identification of animals : By cage number, animal number   and    individual  
 marking by using    Picric acid 
Diet    : Pellet feed supplied by SaiMeera Foods Pvt Ltd,    
                               Bangalore 
Water    : Aqua guard portable water in polypropylene bottles. 
Housing & Environment : The animals were housed in Polypropylene cages  
      provided with bedding of husk. 
Housing temperature :  between 22ºC±3ºC.   
Relative humidity  :  between 30% and 70%, 
Air changes    : 10 to 15 per hour  
Dark and light cycle   : 12:12 hours. 
Duration of the study : 28 Days. 
Table 5  
 SPRCM -SWARNA PUSHPA RASA CHENDHURAM 
Groups No of Rats 
Group I Vehicle control (Water) 12(6male,6 female) 
Group II SPRCM- low dose X (4mg) 12 (6male,6 female) 
Group III SPRCM- Mid dose 5X (20mg) 12 (6male,6female) 
Group IV SPRCM- High dose 10X(40mg) 12(6male,6female) 
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Methodology 
Randomization, Numbering and Grouping of Animals: 
48 Wistar Rats (24M + 24F) were selected and divided into 4 groups. Each 
group consist of 12 animals (Male -6, and Female-6). First group treated as a control 
and other three group were treated with test drug (low, mid, high) for  28 days. 
Animals were allowed acclimatization period of 7 days to laboratory conditions prior 
to the initiation of treatment. Each animal was marked with picric acid. The females 
were nulliparous and non-pregnant. 
 
Justification for Dose Selection: 
         As per OECD guideline three dose levels were selected for the study. They are 
low dose (X), mid dose (5X), high dose (10X). X is calculated by multiplying the 
dose 195mg) and the body surface area of the rat (0.018). i.e X dose is (4mg/kg), 5X 
dose is (20mg/kg), 10X dose is (40mg/kg). 
 
Preparation and Administration of Dose: 
SWARNA PUSHPA RASA CHENDHURAM suspended in with water, It was 
administered to animals at the dose levels of X, 5X, 10X. The test substance 
suspensions were freshly prepared every two days once for 28 days. The control 
animals were administered vehicle only. The drug was administered orally by using 
oral gavage once daily for 28 consecutive days. 
 
Observations: 
Experimental animals were kept under observation throughout the course of 
study for the following: 
 
Body Weight: 
 Weight of each rat was recorded on day 0, at weekly intervals throughout the course 
of study. 
Food and water Consumption: 
 Food and water consumed per animal was calculated for control and the 
treated dose groups.  
 MATERIALS  AND  MATHODS   76 
Clinical signs:  
All animals were observed daily for clinical signs. The time of onset, intensity 
and duration of these symptoms, if any, were recorded. 
Mortality: 
All animals were observed twice daily for mortality during entire course of      
study. 
Necropsy: 
All the animals were sacrificed by excessive anesthesia on day 29. Necropsy 
of all animals was carried out. 
Laboratory Investigations: 
Following laboratory investigations were carried out on day 29 in animals 
fasted over-night. Blood samples were collected from orbital sinus using sodium 
heparin (200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for 
Hematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 
minutes. 
Haematological Investigations: 
Haematological parameters were determined using Haematology analyzer.  
Biochemical Investigations:  
              Biochemical parameters were determined using auto-analyzer. 
Histopathology:  
              Control and highest dose group animals will be initially subjected to 
histopathological investigations. If any abnormality found in the highest dose group 
than the low, then the mid dose group will also be examined. Organs will be collected 
from all animals and preserved in 10% buffered neutral formalin for 24 h and washed 
in running water for 24 h.  The organ sliced 5 or 6µm sections and were dehydrated in 
an auto technicon and then cleared in benzene to remove absolute alcohol. Embedding 
was done by passing the cleared samples through three cups containing molten 
paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. It 
was followed by microtome and the slides were stained withHaematoxylin-eosin red. 
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Statistical analysis:  
Findings such as body weight changes, water and food consumption, 
hematology and blood chemistry were subjected to One-way ANOVA followed by 
dunnet t test using a computer software programme – Graph pad version 7. All data 
were summarized in tabular form, (Table-6 to 12) 
 
 
                     4.6.  PHARMACOLOGICAL ACTIVITY 
DETERMINATION OF INVITRO ANTI PSORIATIC EFFECT OF 
EXTRACTS ON CULTURED HACAT CELL LINES 
Psoriasis is described as the hyper proliferation and aberrant differentiation of 
keratinocytes, which leads to inflammation in dermis and epidermis and leukocyte 
infiltration. Human keratinocytes cell line (HaCaT) is used as an invitro model to 
evaluate anti-psoriatic activities of test molecules. Anti-psoriatic activities are 
measured in terms of inhibition of keratinocytes proliferation 
HaCaT cell lines was purchased from NCCS Pune were maintained in Dulbecco’s 
modified eagles media (HIMEDIA) supplemented with 10% FBS (Invitrogen) and 
grown to confluency at 37°c in 5 % CO2  in a humidified atmosphere in a CO2 
incubator(NBS, EPPENDORF, GERMANY). The cells were trypsinized (500µl of 
0.025% Trypsin in PBS/ 0.5mM EDTA solution (Himedia)) for 2 minutes and 
passaged to T flasks in complete aseptic conditions.   The cells were then grown till 
60% confluency followed by activation with 1µl LPS (1µg/ml). LPS stimulated hacat 
cells were exposed with different concentrations of samples such 
as.6.25,12.5,25,50,100µg/ml from 1mg/ml stock and incubated for 24 hours s. The % 
difference in viability was determined by standard MTT assay after 24 hours of 
incubation. 
 Cells seeding in 96 well plate: 
Two days old confluent monolayer of cells were trypsinized and the cells were 
suspended in 10% growth medium, 100µl cell suspension (5x10
4
 cells/well) 
wasseeded in 96 well tissue culture plate and incubated at 37ºC in a humidified 5% 
CO2 incubator.  
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 Preparation of plant extracts and compound stock: 
 1 mg of each plant extract or compound was added to 1ml of DMEM and 
dissolved completely by cyclomixer. After that the extract solution was filtered 
through 0.22 µm Millipore syringe filter to ensure the sterility.  
 
Antipsoriatic Evaluation: 
.   The cells were then grown till 60% confluency followed by activation with 
1µl LPS (1µg/ml),freshly prepared each plant extracts in 5% DMEM were five times 
serially diluted by two fold dilution (100µg, 50µg, 25µg, 12.5µg, 6.25µg in 100µl of 
5% MEM) and each concentration of 100µl were added in triplicates to the respective 
wells and incubated at 37ºC in a humidified 5% CO2 incubator. 
 
Antipsoriatic Assay by Direct Microscopic observation: 
Entire plate was observed after 24 hours in an inverted phase contrast tissue 
culture microscope (Olympus CKX41 with Optika Pro5 CCD camera)   and 
microscopic observation were recorded as images.  Any detectable changes in the 
morphology of the cells, such as rounding or shrinking of cells, granulation and 
vacuolization in the cytoplasm of the cells were considered as indicators of 
cytotoxicity.    
                                       4.7. CLINICAL STUDY 
This clinical study was conducted after getting approval from IEC Institutional 
ethical committee, GSMC, Chennai. IEC NO: This trial was also registered in (CTRI) 
Clinical Trial Registry of India, CTRI REF NO:. This was done in Post graduate 
Department of SirappuMaruthuvam, Government Siddha Medical College and 
Hospital, Arignar Anna hospital campus,Arumbakkam,Chennai-106 under the 
observation and guidance of Head of the department.   
 
In this clinical study totally 60 cases was enrolled out of which 20 cases were  
treated with Internal and External drugs. 20 cases were treated with both internal, 
external drugs & Prananyamam. 20 cases were treated with External drug and 
Pranayamam. 
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STUDYDESIGN: 
Study Type :An open comparitive clinical trial 
Study Place     : OPD of Arignar Anna Govt. Hospital of Indian medicine  
   attached with Govt. Siddha Medical College,  
    Arumbakkam, Chennai-106. 
Study Period   : 12 Months after completion of Pre-clinical studies.  
Sample Size     :  60 patients (OPD) 
                 20 Patients- Internal, external drugs & Prananyamam. 
      20 Patients - Internal drug & External drugs.              
      20  Patients- External drug and Pranayamam 
   
SUBJECT SELECTION: 
 There is considerable number of patients reporting of OPD of Aringar Anna 
govt. hospital, GSMC, with the symptom of inclusion criteria will be subjected to 
screening test and documented using screening proforma. 
 
INCLUSION CRITERIA: 
 Age : 18 – 60 years. 
  Sex : Both Male and Female 
  Patient willing to sign consent form 
  Willing  to attend OPD for the trial 
 Patches with Scaling. 
 Auspitz Sign + 
 Koebner’s Phenomenon + 
 
EXCLUSION CRITERIA 
HISTORY OF 
 Alcohol 
  Narcotic addicts 
 Anti –malarial drugs 
  Cardiac disease 
  Leprosy 
  Peptic ulcer  
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  SLE, Progressive systemic sclerosis 
  Evidences of secondary infection in the lesions 
  Pregnancy and lactation 
  HIV 
 Syphilis  
  Long term intake of steroids 
 
WITHDRAWAL CRITERIA:  
• Intolerance to the drug and development of any serious adverse effect during 
drug trial.  
• Patient turned unwilling to continue in the course of Clinical trial any other 
systemic illness. 
 
ADR REPORTING:- 
• If ADR is reported patients will be referred to SCRI and the matter will be 
convey to the IEC via member secretary (Peripheral Pharmaco 
vigilancecentre). 
 
MODERN INVESTIGATION: 
Blood: 
Hb, TC, DC, ESR,  
BloodSugar,(R) 
Blood urea. 
Renal Function Tests:  
Urea,   
Creatinine. 
Liver Function Tests: 
Serum total bilirubin, 
Direct bilirubin, 
Indirectbilirubin, 
Alkalinephosphatase,  
SGOT, SGPT.  
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Urine : 
Albumin,  
Sugar,  
Deposits. 
 
CLINICAL ASSESSMENT  
           1. Psoriasis area severity index (PASI) 
 
PSORIASIS AREA AND SEVERITY INDEX (PASI) 
 E – Erythema    
D – Desquamation     
 I – Infiltration 
A – Area 
PASI=0.1(EH+IH+DH)AH+0.2(EU+IU+DU)AU+0.3(ET+IT+DT)AT+0.4(EL+IL+DL)AL 
 
Erythema/ Infiltration/Desquamation scoring  Area scoring  
           
          
0 – Nil        0-Nil 
 
1- Mild       1-Less than 10%  
 
2- Moderate       2- 10%-30%  
 
3-Severe       3-31%-50% 
 
4-Very high       4-51%-70% 
 
5-71%-90%  
 
6-91%-100%  
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PASI SCORE IMAGES: 
 
 Absent Mild Moderate       Severe           Very severe 
 Redness 
  
Score 0 
  
Score 1 
  
Score 2 
  
Score 3                    Score 4 
 
Thickness 
  
Score 0 
  
Score 1 
  
Score 2 
  
Score 3                    Score 4        
Scaling 
  
Score 0 
  
Score 1 
  
Score 2 
  
Score 3               Score 4 
 
PSORIASIS ASSESMENT TOOLS: 
               In this trial Psoriasis area severity index (PASI SCORE
55
) to assess severity 
of psoriasis. 
Mild to Moderate Psoriasis         : PASI < 10 
Moderate Psoriasis                      : PASI 10 ≤ 12 
Moderate to Severe Psoriasis      : PASI 12 ≤ 20 
Severe Psoriasis                          : PASI >20 
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THE CALCULATIONS OF PSORIASIS AREA SEVERITY INDEX (PASI): 
           The Psoriasis area severity index (PASI) is an index used to express the 
severity of Psoriasis. It combines the severity and percentage of affected area 
                                                   Erythema (Redness) – Symbol (E) 
                                                   Induration (Thickness) – Symbol (I) 
Desqumation (Scaling) – Symbol (D) 
                                                   Body surface area involvement - Symbol (A) 
                   Over 4 body regions Head (h) 
                                                 Trunk (t) 
                                                 Upper limb (u) 
                                                 Lower limb (l) 
The PASI score is calculated by the formula: 
PASI=0.1(EH+IH + DH) AH+0.2(EU +IU +DU) AU+0.3(ET + IT+ DT) AT+0.4(EL +IL 
+DL)AL. 
 
PASI SCORE CALCULATION 
PASI SCORE CALCULATION IN SEVERITY OF BODY REGION 
      DEGREE OF SEVERITY IN BODY REGION VALUE 
No symptoms 0 
Slight 1 
Moderate 2 
Marked 3 
Very marked 4 
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PASI SCORE CALCULATION: 
PASI SCORE CALCULATION IN SURFACE AREA INVOLVED         
                                               IN BODY REGION 
SURFACE AREA INVOLVED IN BODY REGION VALUES 
< 10% 1 
10 – 29% 2 
30 -49 % 3 
50 – 69% 4 
70 – 89% 5 
90 – 100% 6 
 
     2. Photo Assessment: 
 Photos of the patient before and after treatment for the evidence of clinical 
improvement. 
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PATIENT SCREENING 
Inclusion/Exclusion 
 
INCLUSION CRITERIA EXCLUSION CRITERIA 
EXCLUDED FROM TRIAL 
METHODOLOGY 
       STUDY NUMBER 
     HISTORY TAKING 
LAB INVESTIGATION 
 TRIAL DRUG  
CLINICAL ASSESSMENT 
OUTCOME 
INFORM ABOUT STUDY 
AND TRIAL DRUG 
 
INFORMED CONSENT FORM 
 
ADVERSE REACTION 
ADVISED TO TAKE 
TREATMENT IN OPD 
ABNORMAL VALUES 
VALUES 
PHARMOCOVIGILANCE 
FURTHER MANAGEMENT OF 
ADVERSE DRUG REACTION 
Both Internal 
and external 
drugs 
 
external drug 
and 
Pranayamam 
 
Internal, 
external drugs 
and 
Pranayamam 
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STUDY ENROLLMENT 
 In this study Patient reporting at the OPD with symptoms of erythema,  
itching, plaques, scaling, Auspitz Sign +, Koebner’s Phenomenon + are chosen for 
enrolment based on this inclusion criteria. 
 
The patients who are to be enrolled would be informed (Form IV) about the 
study, trial drug, possible outcomes and the objectives of the study in the language 
and terms understandable to them. 
After ascertaining the patient’s willingness, informed consent would be 
obtained in writing from them in the consent form (Form IV). All these patients will 
be given Address, Phone number etc. and also the doctor’s phone number, so as to 
report easily any complications arise. 
 Complete clinical history, complaints and duration, examination findings-- all 
would be recorded in the prescribed Proforma in the history and clinical assessment 
forms separately. Screening Form- I will be filled up: Form –II and Form –III will be 
used for recording the patients’ history, clinical examination of symptoms and signs 
and laboratory investigations respectively. Patients would be advised to take the trial 
drug and appropriate dietary advice (Form IV-D) would be given according to the 
patients’ perfect understanding. 
CONDUCT OF THE STUDY: 
 The trial drugs Swarna Puspha Rasa Chendhurum (Internal), Vettiver 
Thailam (External) and Pranayamam are given for 48 days.  OP patients should visit 
the hospital once in 7 days.  At each clinical visit clinical assessment is done and 
prognosis is noted. Sample size is 60 patients. Among 60 patients, 20 Patients are 
treated with Internal and external drugs. 20 Patients are treated with External drug and 
Pranayamam. 20 Patients are treated with Internal, external drugs and Pranayamam. 
The results will be compared at the end of the study. Laboratory investigations are 
done at 0 day & 48
th
 day of the trial. After the end of the treatment, the patient is 
advised to visit the OPD for another 2months for follow-up. 
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DATA COLLECTION FORMS: 
Required information will be collected from each patient by using the following 
forms. 
           FORM l            : Screening Proforma  
FORM II   : History taking Proforma 
FORM III   : Clinical Assessment Proforma 
FORM IV     : Laboratory Investigation Proforma 
FORM V   : Informed Consent Form 
FORM VI   : Withdrawal Form 
FORM VII   : Drug compliance form 
FORM VIII     : Patient Information Sheet 
FORM IX   : Diet sheet 
DATA MANAGEMENT 
After enrolling the patient in the study, a separate file for each patient will be 
opened and all forms will be kept in the file. Study No. and Patient No. will be 
entered on the top of file for easy identification. Whenever study patient visits OPD 
during the study period, the respective patient file will be taken and necessary 
recordings will be made at the assessment form or other suitable form. The screening 
forms will be filed separately. The Data recordings will be monitored for completion 
and adverse event by HOD and Pharmacovigilance committee. All forms will be 
further scrutinized in presence of Investigators by Sr. Research Officer (Statistics) for 
logical errors and incompleteness of data to avoid any bias. No modification in the 
results is permitted for unbiased reports. 
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OUTCOME: 
Primary Outcome: 
• Primary outcome is mainly assessed by reduction in clinical symptoms like 
itching and scaling. 
• PASI Score (Psoriasis area severity index) 
• To evaluate the prevention of recurrence by follow-up after two months from 
the start of intervention. 
• To evaluate the days of outcome with in the treatment of 48 days. 
 
Secondary Outcome: 
• Secondary outcome is assessed by comparing the safety parameters before and 
after treatment. 
 
ETHICAL ISSUES: 
• Informed consent will be obtained from the patients after explaining about the 
clinical trial in regional tongue. 
• After the consent of the patient (through consent form) if they are in the 
inclusion criteria they will be enrolled in the study. 
• Treatment will be provided free of cost. 
• Concomitant medications will be given when required. 
• Rescue medications will be given when needed. 
• The patients who are excluded (as per exclusion criteria) are given proper 
treatment with full care at OPD. 
  
  
BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) & PRANAYAMAM 
  
SI. 
No 
OP. 
NO 
 
AGE/SEX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
N L E ½ 
hr 
1/2
hr 
1hr 1hr      R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 1283 49/F 12.6 12.9 9,200 9,150 64 63 30 32 6 5 32 28 65 52 60 63 
2 1162 30/F 11.0 10.7 10,350 10,500 55 52 38 41 7 5 44 35 57 49 78 76 
3 4228 58/F 13.4 13.2 7,400 8,500 65 61 27 33 8 6 35 33 68 60 104 115 
4 5002 44/F 10.2 10.6 8300 8,400 45 44 48 51 7 5 15 12 29 25 104 110 
5 5104 39/F 11.2 11.0 10,500 10,280 66 64 28 32 6 4 32 29 59 45 95 107 
6 4137 34/F 9.6 9.8 9,100 9,250 57 55 36 40 7 5 17 15 28 24 82 90 
7 1994 28/F 10.4 10.3 9,600 9,800 55 54 40 43 5 3 22 19 48 37 98 92 
8 8354 43/F 8.0 8.2 7,800 7,900 61 58 35 38 4 4 40 33 69 61 118 125 
9 5013 37/F 8.8 8.7 8,700 8,400 53 51 40 44 7 5 25 28 53 56 124 116 
10 2912 53/F 10.6 10.2 10,200 10,300 58 64 36 31 6 5 13 17 26 28 74 85 
11 9115 43/M 14.6 14.8 8,000 8,050 65 50 35 46 4 4 16 14 25 24 80 91 
12 4995 40/M 14.2 14.3 11,000 11,200 67 63 28 34 5 3 23 18 41 37 130 133 
13 3365 42/M 15.1 14.8 8,400 8,250 68 63 27 32 5 5 4 10 8 17 67 73 
14 3435 26/M 15.0 15.2 5,900 6,000 60 61 34 35 6 4 2 4 6 11 95 105 
15 7638 24/M 14.3 14.4 9,600 9,500 64 58 31 39 5 3 14 11 28 24 81 113 
16 4986 30/M 12.4 12.4 8,300 8,500 68 62 24 32 8 6 55 51 96 88 123 119 
17 5087 49/M 14.4 14.5 6,000 6,150 61 58 30 35 9 7 12 16 24 30 96 110 
18 1670 48/M 13.7 13.9 7,600 7,500 58 60 35 36 7 4 23 18 46 39 132 125 
19 3133 30/M 15.0 14.9 9,800 9,750 56 62 38 33 6 5 18 12 33 28 117 105 
20 7137 37/M 13.8 14.0 10,300 10,450 55 58 41 38 4 4 33 28 57 46 98 119 
 BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) 
 
 
SI. 
No 
OP. 
NO 
 
AGE/SEX 
Hb (gm) TC (cu.mm) DC ESR Bl sugar 
N L E ½ 
hr 
1/2
hr 
1hr 1hr      R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 9658 25/M 11.6 11.3 10,300 10,100 66 68 30 28 4 4 6 4 14 12 96 102 
2 7894 42/M 12.8 13.0 8,200 8,400 62 60 32 36 6 4 18 16 32 26 120 116 
3 5612 36/M 15.3 15.2 9,400 9,300 56 59 38 36 6 5 9 8 15 11 110 98 
4 3012 55/M 14.7 14.9 7,600 7,700 52 55 40 40 8 5 22 18 38 27 125 101 
5 9632 45/M 13.6 13.7 9,200 9,600 68 62 28 34 4 4 10 12 22 16 99 120 
6 5284 56/M 12.4 12.1 8,800 9,000 57 60 35 34 7 6 30 32 55 48 121 88 
7 1478 27/M 14.5 14.2 6,200 6,300 63 58 31 37 6 5 28 22 47 38 112 128 
8 4563 46/M 11.9 12.0 9,100 9,200 58 63 37 33 5 4 32 28 61 45 129 103 
9 2354 52/M 11.4 11.7 10,360 10,400 56 52 37 42 7 6 12 10 26 22 90 99 
10 6589 59/M 13.5 13.1 8,300 8,100 69 67 26 29 5 4 15 13 33 24 122 112 
11 1452 36/M 14.8 14.7 9,150 9,300 65 63 29 31 6 6 11 9 23 18 101 120 
12 6325 41/M 11.6 11.9 6,800 7,000 57 56 37 39 6 5 14 18 36 32 110 98 
13 7896 32/M 12.7 12.5 7,200 7,300 70 68 25 28 5 4 30 16 52 48 125 96 
14 7852 51/M 14.5 14.3 11,320 11,400 62 56 30 38 8 6 28 23 56 52 99 110 
15 2365 28/F 10.7 10.9 9,200 9,300 73 71 21 24 6 5 19 11 44 36 128 112 
16 2031 55/F 11.3 11.1 8,100 8,400 55 62 38 32 7 6 36 27 60 52 119 131 
17 9630 59/F 10.8 11.0 7,500 7,100 58 57 37 36 5 5 48 31 69 62 124 114 
18 7456 25/F 13.5 13.7 9,600 9,800 53 55 39 41 8 4 33 26 54 51 97 104 
19 2368 43/F 12.4 12.1 10,200 10,300 63 61 31 34 6 5 23 19 55 47 102 108 
20 3148 27/F 11.1 11.4 8,400 8,200 67 58 28 38 5 4 31 24 59 43 130 126 
 BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH  
VETTIVER THYLAM (EXT) & PRANAYAMAM 
SI. 
No 
OP. 
NO 
AGE/SEX 
Hb (gm) TC (cu.mm) 
DC ESR Bl sugar 
N L E ½ 
hr 
1/2
hr 
1hr 1hr      R 
BT AT BT AT BT AT BT AT BT AT BT AT BT AT BT AT 
1 5086 25/M 15.2 15.3 7,100 7,250 56 61 37 35 7 4 10 8 19 16 114 98 
2 5268 45/M 14.3 14.0 8,800 9,000  
 
74 70 20 26 6 4 18 16 32 34 186 160 
3 9920 42/M 16.0 16.1 6,600 6,900 55 60 37 35 8 5 6 8 15 13 126 130 
4 4570 57/M 13.3 13.6 9,600 9,150 72 68 23 29 5 3 12 10 24 27 163 117 
5 5460 49/M 10.8 11.0 11,400 11,300 63 65 32 30 5 5 20 22 37 34 90 95 
6 5171 45/M 12.3 12.5 7,300 7,600 52 58 42 38 6 4 35 37 59 44 156 137 
7 7369 31/M 14.7 14.8 8,100 8,300 58 48 37 49 5 3 61 55 96 88 110 140 
8 3107 42/M 15.9 16.0 10,200 10,450 61 65 34 31 5 4 6 8 15 12 106 98 
9 3109 59/M 15.1 15.3 7,200 7,500 65 60 29 35 6 5 18 14 40 32 95 110 
10 2798 18/M 10.6 10.7 11,200 11,050 69 65 26 30 5 5 24 18 50 41 123 131 
11 1392 39/F 11.3 11.4 9,560 9,500 53 57 40 37 7 6 35 27 58 48 148 120 
12 2102 40/F 14.3 14.5 8,350 8,200 64 67 33 30 3 3 45 32 65 56 98 88 
13 769 38/F 12.3 12.5 7,550 7,370 55 52 37 44 8 4 62 43 94 72 106 122 
14 2580 50/F 11.8 12.0 10,300 10,450 57 62 37 33 6 5 25 17 55 38 99 105 
15 6566 22/F 12.3 12.5 7,360 7,300 56 69 37 25 7 6 12 10 34 28 110 101 
16 5931 36/F 11.9 11.8 8,310 8,500 51 58 44 38 5 4 27 23 43 37 123 120 
17 3124 50/F 13.5 13.4 9,630 9,100 62 60 33 36 5 4 32 28 64 42 99 110 
18 5469 33/F 11.5 11.3 11,850 11,200 76 54 18 40 6 6 16 14 38 32 138 125 
19 5224 45/F 12.8 12.6 9,300 9,500 68 56 24 40 8 4 28 25 49 37 98 105 
20 3001 38/F 11.6 11.5 10,520 10,200 70 61 23 30 7 9 47 38 72 64 95 125 
 URINE ANALYSIS FOR OPD PATIENTS TREATED WITH SWARNA 
PUSHPA RASA CHENDHURAM (INT) &VETTIVER THYLAM (EXT) 
S.N
O 
OP.N
O 
AGE/S
EX 
URINE ANALYSIS BEFORE 
TREATMENT 
URINE ANALYSIS AFTER TREATMENT 
   ALBU
MIN 
SUGAR DEPOSITS ALBUMI
N 
SUGA
R 
DEPOSITS 
     PUS 
CEL
LS 
EPITHEL
IAL 
CELLS 
  PUS 
CELLS 
EPITHELIA
L CELLS 
1 9658 25/M NIL NIL NIL  2-3  NIL NIL    NIL     NIL  
2 7894 42/M NIL NIL NIL  2-3  NIL NIL 0-1  2-6 
3 5612 36/M NIL NIL 1-2 NIL  NIL NIL 1-2  2-5  
4 3012 55/M NIL NIL NIL    1-3 NIL NIL 2-5  1-2  
5 9632 45/M NIL NIL 1-3  NIL  NIL NIL 1-3  2-3  
6 5284 56/M NIL NIL 0-1  0-2  NIL NIL     NIL     NIL  
7 1478 27/M NIL NIL NIL      4-6 NIL NIL 2-4  0-1  
8 4563 46/M NIL NIL NIL  NIL  NIL NIL NIL     NIL  
9 2354 52/M NIL NIL NIL  4-5  NIL NIL 2-3  4-5  
10 6589 59/M NIL NIL 0-4  NIL  NIL NIL 1-3     NIL  
11 1452 36/M NIL NIL NIL     3-4 NIL NIL 1-4     NIL  
12 6325 41/M NIL NIL NIL  NIL  NIL NIL 0-3     NIL  
13 7896 32/M NIL NIL 0-1  1-2  NIL NIL 0-2     NIL  
14 7852 51/M NIL NIL 2-3 NIL  NIL NIL NIL      NIL  
15 2365 63/F NIL NIL NIL  NIL  NIL NIL NIL  1-2  
16 2031 55/F NIL NIL 1-3  1-2  NIL NIL 2-3  1-2  
17 9630 59/F NIL NIL NIL  NIL  NIL NIL NIL  NIL  
18 7456 25/F NIL NIL NIL  NIL  NIL NIL 3-5  6-7  
19 2368 43/F NIL NIL NIL 2-5  NIL NIL 0-1  1-2  
20 3148 27/F NIL NIL NIL  NIL  NIL NIL 3-5    3-4 
 URINE ANALYSIS FOR OPD PATIENTS TREATED WITH SWARNA 
PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) & 
PRANAYAMAM 
S.N
O 
OP.N
O 
AGE/S
EX 
URINE ANALYSIS BEFORE 
TREATMENT 
URINE ANALYSIS AFTER TREATMENT 
   ALBU
MIN 
SUGAR DEPOSITS  
ALBUMI
N 
SUGA
R 
DEPOSITS 
     PUS 
CEL
LS 
EPITHEL
IAL 
CELLS 
  PUS 
CELLS 
EPITHELIA
L CELLS 
1. 1283 49/F NIL NIL  NIL    0-3 NIL NIL 2-3  3-5  
2. 1162 30/F NIL NIL 2-3 NIL  NIL NIL 2-3  NIL  
3. 4228 58/F NIL NIL 1-2     1-3 NIL NIL NIL       2-3 
4. 5002 44/F NIL NIL 2-4  NIL  NIL NIL   2-3 NIL  
5. 5104 39/F NIL NIL 2-3  1-3  NIL NIL NIL  1-3  
6. 4137 34/F NIL NIL NIL 0-1  NIL NIL 1-2       NIL  
7. 1994 28/F NIL NIL 2-5  NIL  NIL NIL     4-6 NIL  
8. 8354 43/F NIL NIL NIL     3-5  NIL NIL NIL  NIL  
9. 5013 37/F NIL NIL 1-3  NIL  NIL NIL 3-5 NIL  
10. 2912 53/F NIL NIL 1-4 0-4  NIL NIL NIL  0-4  
11. 9115 43/M NIL NIL 2-4  NIL  NIL NIL    3-4 NIL  
12 4995 40/M NIL NIL 1-3  2-4 NIL NIL NIL  NIL  
13 3365 42/M NIL NIL 0-2  0-1  NIL NIL 1-2  0-1  
14 3435 26/M NIL NIL NIL  2-3 NIL NIL NIL       2-3 
15 7638 24/M NIL NIL NIL  NIL  NIL NIL NIL  NIL  
16 4986 30/M NIL NIL 2-3  1-3  NIL NIL 1-2  1-3  
17 5087 49/M NIL NIL NIL  NIL  NIL NIL NIL  NIL  
18 1670 48/M NIL NIL 3-5  NIL  NIL NIL 4-6 3-4  
19 3133 30/M NIL NIL 0-1  NIL NIL NIL 2-5        2-3 
20 7137 37/M NIL NIL   3-4 NIL  NIL NIL 1-3      3-5  
 URINE ANALYSIS FOR OPD PATIENTS TREATED WITH  VETTIVER 
THYLAM (EXT) & PRANAYAMAM 
S.N
O 
OP.N
O 
AGE/S
EX 
URINE ANALYSIS BEFORE 
TREATMENT 
URINE ANALYSIS AFTER TREATMENT 
   ALBU
MIN 
SUGAR DEPOSITS  
ALBUMI
N 
SUGA
R 
DEPOSITS 
     PUS 
CEL
LS 
EPITHEL
IAL 
CELLS 
  PUS 
CELLS 
EPITHELIA
L CELLS 
1 5086 25/M NIL NIL 2-4  NIL  NIL NIL 2-3       3-4 
2 5268 45/M NIL NIL 1-3      2-4 NIL NIL 2-3       1-4 
3 9920 42/M NIL NIL 0-2  0-1  NIL NIL NIL       0-3 
4 4570 57/M NIL NIL NIL      2-3 NIL NIL   2-3 NIL  
5 5460 49/M NIL NIL NIL  NIL  NIL NIL NIL  1-3  
6 5171 45/M NIL NIL 2-3  1-3  NIL NIL 1-2       NIL  
7 7369 31/M NIL NIL NIL  NIL  NIL NIL     0-2      4-5 
8 3107 42/M NIL NIL 3-5  NIL  NIL NIL NIL  NIL  
9 3109 59/M NIL NIL 0-1    NIL NIL NIL 3-4 NIL  
10 2798 18/M NIL NIL   3-4    NIL  NIL NIL NIL  2-4  
11 1392 39/F NIL NIL 2-3  3-5  NIL NIL     NIL        1-3 
12 2102 40/F NIL NIL 2-3  NIL  NIL NIL 2-3 NIL  
13 769 38/F NIL NIL NIL       2-3 NIL NIL 1-2       1-3 
14 2580 50/F NIL NIL  2-3 NIL  NIL NIL 2-4  NIL  
15 6566 22/F NIL NIL NIL  1-3  NIL NIL 2-3  1-3  
16 5931 36/F NIL NIL 1-2       NIL  NIL NIL    NIL 0-1  
17 3124 50/F NIL NIL  4-6 NIL  NIL NIL 2-5  NIL  
18 5469 33/F NIL NIL NIL  NIL  NIL NIL    NIL        3-5  
19 5224 45/F NIL NIL 3-5 NIL  NIL NIL 1-3  NIL  
20 3001 56/F NIL NIL NIL  0-4  NIL NIL     0-3       1-4 
 
 LIVER FUNTION TEST FOR OPD PATIENTS TREATED WITH     
SWARNAPUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) &PRANAYAMAM 
 
 
 
S.NO 
 
 
 
OP.NO 
 
 
 
AGE/SEX 
 
LIVER FUNCTION TEST – BEFORE TREATMENT 
 
LIVER FUNCTION TEST – AFTER TREATMENT 
TOTAL 
BILUR
UBIN 
DIRECT 
BILURU
BIN 
INDIRE
CT 
BILURU
BIN 
SGO
T 
SGP
T 
SERUM 
ALKALIN
E 
PHOSPHA
TASE 
TOTAL 
BILURUBI
N 
DIREC
T 
BILUR
UBIN 
INDIREC
T 
BILURU
BIN 
SGOT SGPT SERUM 
ALKALINE 
PHOSPHAT
ASE 
1. 1283 49/F 0.56 0.32 0.23 46 52 78 0.61 0.16 0.56 45.3 46.3 85 
2. 1162 30/F 0.55 0.03 0.44 28.2 45.1 71 0.43 0.23 0.21 29.2 47 66 
3. 4228 58/F 0.81 0.42 0.36 21 12 96 0.74 0.44 0.36 14 16 75 
4. 5002 44/F 0.63 0.39 0.32 34 13 82 0.59 0.32 0.25 36 9 76 
5. 5104 39/F 0.74 0.31 0.31 46 24 78 0.64 0.36 0.38 38 29 73 
6. 4137 34/F 0.7 0.41 0.24 35 26 101 0.6 0.2 0.4 13 16 96 
7. 1994 28/F 0.61 0.33 0.39 41 14 104 0.52 0.37 0.29 33 29 82 
8. 8354 43/F 0.52 0.11 0.47 18.1 16.2 83 0.56 0.06 0.44 12 16 71 
9. 5013 37/F 0.9 0.2 0.7 18 23 96 0.8 0.24 0.64 13 22 111 
10. 2912 53/F 0.8 0.4 0.4 17 18 128 0.7 0.2 0.5 10 15 105 
11. 9115 43/M 0.86 0.19 0.66 21.4 17.6 525 0.7 0.6 0.3 21.1 16.8 46 
12 4995 40/M 0.4 0.1 0.3 20 14 69 0.5 0.1 0.1 18 24 75 
13 3365 42/M 0.97 0.54 0.35 43 24 94 0.3 0.3 0.3 25 23 93 
14 3435 26/M 0.75 0.52 0.23 35 28 86 0.61 0.12 0.50 20 19.2 71 
15 7638 24/M 0.59 0.39 0.27 28 19 74 0.49 0.24 0.22 36 12 76 
16 4986 30/M 0.61 0.31 0.35 37 14 95 0.58 0.36 0.23 23 23 89 
17 5087 49/M 0.6 0.4 0.2 12 18 57 0.8 0.5 0.3 18 19 65 
18 1670 48/M 0.73 0.41 0.37 46 31 72 0.54 0.39 0.24 44 27 51 
19 3133 30/M 0.72 0.43 0.29 35 12 56 0.68 0.44 0.29 26 11 85 
20 7137 37/M 0.9 0.4 0.5 16.1 18.5 49.1 0.7 0.33 0.38 13 16.2 50.3 
 LIVER FUNTION TEST FOR OPD PATIENTS TREATED WITH     
SWARNAPUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) 
 
 
 
S.NO 
 
 
 
OP.NO 
 
 
 
AGE/SEX 
 
LIVER FUNCTION TEST – BEFORE TREATMENT 
 
LIVER FUNCTION TEST – AFTER TREATMENT 
TOTAL 
BILUR
UBIN 
DIRECT 
BILURU
BIN 
INDIRE
CT 
BILURU
BIN 
SGO
T 
SGP
T 
SERUM 
ALKALIN
E 
PHOSPHA
TASE 
TOTAL 
BILURUBI
N 
DIREC
T 
BILUR
UBIN 
INDIREC
T 
BILURU
BIN 
SGOT SGPT 
SERUM 
ALKALINE 
PHOSPHAT
ASE 
1. 9658 25/M 0.2  0.32  0.17  21  20  51  0.4  0.2  0.2  19  31.5 56 
2. 7894 42/M 0.96  0.24  0.68  43.8  29.7 86  0.8  0.59  0.22 42  29.6 81 
3. 5612 36/M 0.94  0.59  0.49  22  21  51  0.57  0.01  0.49 19  17  56 
4. 3012 55/M 0.4  0.3  0.1  28  17  45  2.41  1.23  1.11 20  15  32 
5. 9632 45/M 0.92  0.23  0.64  25.4  26  75  0.4  0.3  0.1  22.3  19.3  80  
6. 5284 56/M 0.55  0.04  0.46  28.9  54.6  54  0.57  0.04  0.51  25.2  39.2 39.3  
7. 1478 27/M 0.46  0.24  0.2  22.9  19 56  0.4  0.2  0.2  20.1  15  59  
8. 4563 46/M 0.62  0.35  0.34  17.9  15  48  0.70  0.44  0.31 16.8  12  41 
9. 2354 52/M 1.69  0.93  0.63  20  22  98  0.68  0.11  0.56  17  18.8  88 
10. 6589 59/M 0.31  0.08  0.30  19.4  6.9  90  0.33  0.01  0.29 15.9  6.2 88 
11. 1452 36/M 0.79  0.51  0.20  34  16  59  0.58  0.46  0.34  25 18 49 
12 6325 41/M 0.55  0.36  0.26  19  16  31  0.43  0.22  0.25 11 12 41 
13 7896 32/M 0.64  0.31  0.30  29  19  55  0.58  0.35  0.23  22 13 59  
14 7852 51/M 2.49  1.25  1.17  20  12  211  1.60  0.95  0.64 21  34 114  
15 2365 63/F 0.4  0.1  0.3  30  45  162  0.5  0.3  0.2  15 26 88  
16 2031 55/F 0.41  0.04  0.39  18.4  17.5  63  0.4  0.3  0.1  20  10.1  58  
17 9630 59/F 0.40 0.2  0.2  29.3  15  55  0.5  0.3  0.2  18.9  11 45 
18 7456 25/F 0.73  0.39  0.34  32  19  54  0.68  0.35  0.31 26 12 54 
19 2368 43/F 0.57  0.34  0.21  33  23  62  0.49  0.34  0.14  32  23 41 
20 3148 27/F 0.61  0.33  0.30  40  40  61  0.55  0.35  0.23 34 34 56 
  
  
RENAL FUNCTION TEST FOR OPD PATIENTS TREATED WITH 
SWARNA PUSHPA RASA CHENDHURAM (INT),  
VETTIVER THYLAM (EXT) 
 
 
 
 
 
 
 
S.NO 
 
 
OP.NO 
 
 
AGE/SEX 
RENAL FUNCTION TEST 
BEFORE TREATMANT AFTER TREATMANT 
UREA CREATININE UREA CREATININE 
1 9658 25/M 18 0.6 21 0.5 
2 7894 42/M 20 0.5 22 0.4 
3 5612 36/M 16 0.7 20 0.7 
4 3012 55/M 24 0.4 20 0.5 
5 9632 45/M 22 0.6 18 0.6 
6 5284 56/M 20 0.6 23 0.5 
7 1478 27/M 18 0.4 21 0.3 
8 4563 46/M 24 0.7 24 0.6 
9 2354 52/M 25 0.4 22 0.5 
10 6589 59/M 18 0.5 20 0.6 
11 1452 36/M 20 0.6 18 0.4 
12 6325 41/M 19 0.5 23 0.7 
13 7896 32/M 15 0.3 20 0.5 
14 7852 51/M 21 0.7 15 0.6 
15 2365 63/F 14 0.4 14 0.3 
16 2031 55/F 20 0.4 22 0.6 
17 9630 59/F 23 0.5 25 0.4 
18 7456 25/F 19 0.7 23 0.7 
19 2368 43/F 22 0.5 20 0.4 
20 3148 27/F 18 0.4 16 0.4 
  
 
RENAL FUNCTION TEST FOR OPD PATIENTS TREATED WITH SWARNA  
PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) & 
PRANAYAMAN 
 
 
 
 
 
 
S.NO 
 
 
OP.NO 
 
 
AGE/SEX 
RENAL FUNCTION TEST 
BEFORE TREATMANT AFTER TREATMANT 
UREA CREATININE UREA CREATININE 
1. 1283 49/F 18 0.6 18 0.5 
2. 1162 30/F  24 0.4 23 0.4 
3. 4228 58/F 20 0.4 22 0.6 
4. 5002 44/F 30 0.7 28 0.5 
5. 5104 39/F 22 0.5 18 0.4 
6. 4137 34/F 24 0.6 20 0.7 
7. 1994 28/F 18 0.5 18 0.6 
8. 8354 43/F 20 0.4 24 0.5 
9. 5013 37/F 24 0.5 20 0.6 
10. 2912 53/F 18 0.4 16 0.4 
11. 9115 43/M 22 0.6 25 0.7 
12 4995 40/M 23 0.2 20 0.4 
13 3365 42/M 24 0.5 24 0.5 
14 3435 26/M 15 0.4 18 0.6 
15 7638 24/M 26 0.6 20 0.7 
16 4986 30/M 24 0.6 21 0.4 
17 5087 49/M 18 0.5 22 0.4 
18 1670 48/M 16 0.4 20 0.5 
19 3133 30/M 18 0.6 16 0.7 
20 7137 37/M 21 0.5 23 0.4 
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                                           STATISTICAL ANALYSIS 
CLINICAL PROGNOSIS 
Clinical Features for OPD Patients Treated with Swarna Pushpa Rasa 
Chendhuram (Int), VettiverThylam (Ext) & Pranayaman.  
The most popular non parametric statistical tool, namely, McNemar Test 
analysis has been employed to analyses the effectiveness with the help of a 
hypothesis. 
 
S. 
No 
Clinical features Before Treatment After Treatment 
n% n% 
1. Erythematous 
patcheswithwhitesil 
Very scales 
60(100) 4(6.5)** 
2. Itching 45(75) 0(0)** 
3. Scalp lesions  18(30) 0(0)** 
4. Auspitz sign 52(86.5) 2(3.5)** 
5. Candlegrease sign 14(23.5) 0(0)** 
6. Kobner’s phenomenon 25(41.6) 3(5)** 
7. Nail changes  8(13.5) 3(5)* 
8. Palm and sole lesions  21(35) 0(0)** 
9. Joint involvement. 5(8.5) 1(2.5)*  
McNemat test, C.I: 95%,  *P<0.05; **P<0.01 
Software: spss17 version 
Number of cases: 40 
Inference:  
Since the p value is significant in all clinical features.  So there is significant 
reducing of clinical features among the patients for the treatment of Thadippu Perunoi 
(Psoriasis).Hence it is concluded that the treatment was effective and significant. 
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LIVER FUNTION TEST FOR OPD PATIENTS TREATED WITH    
SWARNAPUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM 
(EXT) & PRANAYAMAM 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Total bilirubin 0.69±0.15 0.60±0.12 <0.05 
2 SGPT 21.97±10.64 21.82±10.17 0.919 
3 SGOT 29.89±11.31 24.38±11.11 <0.05 
4 Alkaline Phosphatase 81.70±18.97 77.06±17.11 0.146 
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 representsstatistically 
significant. 
 
 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Total bilirubin 0.73±0.52 0.67±0.48 0.684 
2 SGPT 22.68±11.60 19.83±9.47 0.149 
3 SGOT 26.70±7.39 22.11±7.17 <0.001 
4 Alkaline Phosphatase 73.35±42.55 61.26±21.53 0.056 
 
C.I: 95%; Paired samples t test. Where p<0.001, p<0.05 representsstatistically 
significant. 
 
 
BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH 
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER 
THYLAM (EXT). 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 19.80±2.98 20.35±2.94 0.457 
2 Creatinine 0.52±0.12 0.51±0.12 0.716 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 representsstatistically 
significant.  
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BLOOD ANALYSIS FOR OPD PATIENTS TREATED WITH SWARNA 
PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) 
&PRANAYAMAN. 
 
S.No. Investigations Before 
Treatment 
Mean±SD 
n= 20 
After 
Treatment 
Mean±SD 
n= 20 
P value 
1 Urea 21.25±3.72 20.80±3.10 0.527 
2 Creatinine 0.49±0.11 0.52±0.11 0.301 
 
C.I: 95%; Paired samples t test. Where  p<0.001, p<0.05 representsstatistically 
significant. 
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PASI SCORE FOR OPD PATIENTS TREATED WITH SWARNA PUSHPA 
RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) & 
PRANAYAMAN. 
S.No. BT 
PASI  
Score 
AT 
PASI  
Score 
1 16.2 4.0 
2 31.8 4.6 
3 19.4 4.1 
4 4.8 1.0 
5 22.8 6.8 
6 4.8 0 
7 32.8 8.2 
8 27.2 0 
9 30.9 3.4 
10 2.7 0.6 
11 42.4 4.8 
12 22.6 5.7 
13 27.3 2 
14 12 13.4 
15 14.4 0 
16 20.2 7.4 
17 41.6 4.4 
18 4.8 0 
19 14 1.8 
20 21.3 0 
 
Software: spss17 version 
Variables:PASI Score – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.30 
Before and after treatment mean difference: 17.09 ± 11.24. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment of Thadippu Perunoi 
(Psoriasis).Hence it is concluded that the treatment was effective and significant. 
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PASI SCORE FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT),  
VETTIVER THYLAM (EXT). 
S.No. BT 
PASI  
Score 
AT 
PASI  
Score 
1 14.4 0 
2 21.6 5.2 
3 60 10.8 
4 15.6 0 
5 13.6 5.4 
6 21 0 
7 11.8 0.8 
8 11.8 3.2 
9 60 6.4 
10 57 7.0 
11 21.1 0.6 
12 23.5 4.6 
13 10.8 0 
14 23.2 4.8 
15 24.6 0 
16 8.8 2.8 
17 21.3 0 
18 14.4 8 
19 16.4 2.2 
20 18.8 4.8 
Software: spss17 version 
Variables: PASI Score – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.61 
Before and after treatment mean difference: 20.15 ± 14.24. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant reducing of 
PASI Score among the patients for the treatment of Thadippu Perunoi 
(Psoriasis).Hence it is concluded that the treatment was effective and significant. 
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PASI SCORE FOR OPD PATIENTS TREATED WITH  
VETTIVER THYLAM (EXT) & PRANAYAMAM 
S.No. BT 
PASI  
Score 
AT 
PASI  
Score 
1 14.4 8 
2 16.4 2.2 
3 18.8 4.8 
4 16.2 4.0 
5 31.8 4.6 
6 19.4 4.1 
7 4.8 1.0 
8 22.8 6.8 
9 60 10.8 
10 15.6 0 
11 13.6 5.4 
12 57 7.0 
13 21.1 0.6 
14 23.5 4.6 
15 10.8 0 
16 23.2 4.8 
17 21.3 0 
18 42.4 4.8 
19 22.6 5.7 
20 18.8 4.8 
Software: spss17 version 
Variables: PASI Score – before treatment, after treatment 
Number of cases: 20 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.611 
Before and after treatment mean difference: 19.52 ± 12.60. 
P Value (2 tailed): p<0.001. 
Inference:  
Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment of Thadippu Perunoi 
(Psoriasis).Hence it is concluded that the treatment was effective and significant. 
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5. RESULTS AND OBSERVATION 
 
SPRC – ORGANOLEPTIC CHARACTER 
 
S.NO  CHARACTERS  RESULTS  
1     COLOUR  Brick red  
2     TASTE  Tasteless  
3     ODOUR  Odourless 
4     APPERENCE  Fine powder  
5     SOLUBILITY  Soluble in water and alcohol  
 
COLOUR OF THE INGREDIENT BEFORE & AFTER PURIFICATION 
S.  
NO  
INGREDIENTS           BEFORE       
PURIFICATION  
          AFTER      
PURIFICATION  
1  Rasam Colourless,  dust  float  
over it  
Colourless 
2  Gandhagam Yellow solid  yellow granules  
3 Velvangam Sliver solid Sliver 
4 Navacharam Greenish Greenish 
 
         TRADITIONALTESTING METHOD FOR CHENDHURAM 
S.  
NO  
            TESTS  INFERENCE  
1  Floating of water       +  
2  Finger furrows test       +  
3  Lusterless       +  
4  Tasteless       +  
5  Colour Brick red  
 
OBSERVATION 
Hence it proves the traditional way to testing.  
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                       PHYSICO-CHEMICAL ANALYSIS  
PHYSICO-CHEMICAL ANALYSIS RESULTS  FOR  SPRC 
S.NO  PARAMETERS  MEAN RESULTS  
1  Loss on drying at 105
0
C  7.32%  
2  Total ash  88.29%  
3  Water soluble ash  30.73%  
4  Acid soluble ash  50.75%  
5  PH 3.91 
 
HEAVY METAL ANALYSIS 
 
S.NO HEAVY METALS RESULTS 
1 Mercury No detectable 
2 Lead  No  detectable 
3 Arsenic No detectable 
4 Cadmium No detectable 
5 Chromium No detectable 
 
OBSERVATION : 
Hg ,Pb, As, Cd, Chromium is No detectable limit.  Hence it proves the drug is safe for 
Internal Administration. 
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Acute oral toxicity study of SWARNA PUSHPA RASA CHENDHURAM 
 
Dose finding experiment and its behavioral Signs of acute oral Toxicity 
 
Observation done: 
SL Group  CONTROL Observation 
Group 
TEST GROUP 
Observation 
1 Body weight Normal Body weight Normally increased 
 
2 Assessments of posture Normal Assessments of posture Normal 
3 Signs of Convulsion 
Limb paralysis 
Normal Signs of Convulsion 
Limb paralysis 
Absence of sign (-) 
4 Body tone Normal Body tone Normal 
5 Lacrimation Normal Lacrimation Absence 
6 Salivation Normal Salivation Absence 
7 Change in skin color No significant 
color change 
Change in skin color No significant color 
change 
8 Piloerection Normal Piloerection Normal 
9 Defecation Normal 
 
Defecation Normal 
 
10 Sensitivity response Normal Sensitivity response Normal 
11 Locomotion Normal Locomotion Normal 
12 Muscle gripness Normal Muscle gripness Normal 
13 Rearing Mild Rearing Mild 
14 Urination Normal Urination Normal 
 
Results: 
 All data were summarized in tabular form, (Table-1-4) showing for each test 
group the number of animals used, the number of animals displaying signs of toxicity, 
the number of animals found dead during the test, description of toxic symptoms, 
weight changes, food and water intakeNo of animals in each group:3 
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(Observational study Results) 
 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. Control + - - + - + - - - - - - - - - - - - - - 
2. 
4mg 
 
+ - - + - + - - - - - - - - - - - - - - 
 
1..Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch 
Response 7. Decreased Motor Activity 8.Tremors 9.Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14.Analgesia 15.Lacrimation 
16.Exophthalmos 17.Diarrhea 18.Writhing 19.Respiration 20.Mortality. 
(+  Present, -  Absent) 
 
( Body weight Observation) 
 
 
 
 
 
 
 
(Water intake (ml/day) of Wistar albino rats group exposed to  
SWARNA PUSHPA RASA CHENDHURAM): 
DOSE 
 
DAYS 
1 6 14 
CONTROL 60 ± 1.62 60±1.10 60.1±1.04 
HIGH DOSE 59.5±1.04 59.5±2.07       59.8±2.04 
P value (p)* NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D 
(One-way ANOVA followed by Dunnett’s test) 
DOSE 
 
DAYS 
1 7 14 
CONTROL 270.1±65.70  270.7± 09.71 270.6 ±2.10 
HIGH DOSE 260.3± 4.44 260.4 ±7.12 260.2 ± 6.05 
P value (p)* NS NS NS 
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Food intake (gm/day) of Wistar albino rats group exposed to  
SWARNA PUSHPA RASA CHENDHURAM 
DOSE 
 
DAYS 
1 7 14 
CONTROL 62.4±1.54 62.2±1.62 62.7±4.06 
High DOSE 64.0±2.24 64.4±2.10 64.6±2.70 
 
SUB -ACUTE TOXICITY 
Repeated Dose 28- day oral toxic study ofSWARNA PUSHPA RASA 
CHENDHURAM 
Body weight of wistar albino rats group exposed to SWARNA PUSHPA RASA 
CHENDHURAM 
NS- Not Significant, **(p > 0.01),*(p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
 
Water intake (ml/day) of Wistar albino rats group exposed to SWARNA PUSHPA RASA 
CHENDHURAM 
 
DOSE 
 
DAYS 
1 6 14 21 28 
CONTROL 56.4 ± 2.34      56.2±1.07 56.7±1.30 56.8±1.10 56.4±1.70 
LOW DOSE 63.6±1.81 63.6±2.43 63.6±1.72 63.7±2.36 63.7±1.30 
MID DOSE 64.2±2.21 64.2±1.21 64.1±2.52 64.4±1.42 64.4±1.74 
HIGH DOSE 58.2±3.40 58.2±1.42 58.4±1.44 58.6±1.78 58.8±2.62 
P value (p)* NS NS NS NS NS 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
DOSE 
 
DAYS 
1 7 14 21 28 
CONTROL 282.2±05.64 282.2 ± 10.04 282.4 ± 12.40 282.4± 14.40 282.2 ± 12.10 
LOW DOSE 280.7 ± 57.75 280.4 ± 4.19 281.3± 5.21 282 ±1.40 282.6± 6.16 
MID DOSE 281.1± 1.22 281.2 ± 2.21 281.2 ± 1.42 282.2 ± 5.08 282.4 ± 13.12 
HIGH DOSE 275.2± 2.41 275.4±3.17 275.8 ± 2.64 276.2 ± 4.18 277 ± 3.30 
P value (p)* NS NS NS NS NS 
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Food intake (gm/day) of Wistar albino rats group exposed to  
SWARNA PUSHPA RASA CHENDHURAM 
DOSE 
 
DAYS 
2 7 23 22 28 
CONTROL 61±3.01 61.2±2.11 61.4±3.11 61.4.2±3.42 61±3.40 
LOW DOSE 59.5±7.12 59.5±1.44 59.6±1.50 59.4±1.20 59.8±1.92 
MID DOSE 60.2±6.70 60.2±2.20 60.6±2.24 60.6±1.46 60.7±1.74 
HIGH DOSE 64.3±1.55 64.6±1.54 64.8±2.16 65.1±1.50 65.1±1.72 
P value (p)* NS NS NS NS NS 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test 
 
Haematological parameters of Wistar albino rats group exposed to SWARNA 
PUSHPA RASA CHENDHURAM 
 
Category Control Low dose Mid dose High dose P value (p)* 
Haemoglobin(g/dl) 34.6±0.43 34.6±0.30 34.6±0.13 34.6±0.23 N.S 
Total WBC  
(×10
3   
l) 
9.1±0.40 9.12±0.01 9.1±0.08 9.13±1.30 N.S 
Neutrophils (%) 15.1±0.20 15.12±0.23 15.13±1.06 15.14±1.07 N.S 
lymphocyte (%) 80.10±1.36 80.10±1.20 80.12±1.24 81.20±1.34 N.S 
Monocyte (%) 0.01±0.02 0.01±0.01 0.01±0.04 0.01±0.03 N.S 
Eosinophil (%) 0.04±0.06 0.04±0.03 0.04±0.05 0.04±0.07 N.S 
Platelets cells10
3
/µl 1400.1±1.08 1400.3±4.84 1400.2±4.60 1400.4±6.32 N.S 
Total RBC 10
6
/µl 9.32±0.64 9.32±0.652 9.65±0.08 9.66±0.05 N.S 
PCV% 34.60±0.8 34.63±6.23 34.6±1.31 34.8±8.22 N.S 
MCHC g/Dl 35.2±1.42 35.4±1.22 35.6±1.52 35.8±1.23 N.S 
MCV fL(µm
3
) 54.8±1.21 54.8±1.20 54.6±1.11 54.7±1.10 N.S 
 
N.S- Not Significant, **(p > 0.01), *(p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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Biochemical Parameters of Wistar albino rats group exposed to  
SWARNA PUSHPA RASA CHENDHURAM 
BIOCHEMICAL 
PARAMETERS 
CONTROL 
LOW 
DOSE 
MID DOSE HIGH DOSE P Value (p)* 
GLUCOSE (R) (mg/dl) 85.10±1.22 85.13±1.31 85.6±.04 85.7±6.20 N.S 
T.CHOLESTEROL(mg
/dl) 
105.10±3.10 105.15±2.20 105.10±1.17 105.11±13 N.S 
TRIGLY(mg/dl) 76.03±1.04 76.04±1.32 76.05±1.32 76.06±1.04 N.S 
LDL 69.2±4.13 69.4±1.45 69.3±1.23     69.4±2.22 NS 
VLDL 14.6±1.30 14.6±1.42 14.6±1.22 14.4±1.24 NS 
HDL 24.12±2.30 24.12±2.30 24.16±1.42 24.65±1.34 NS 
Ratio 
1(T.CHO/HDL) 
5.1±1.10 5.1±1.20 5.1±1.30 5.1±1.60 NS 
Ratio 2(LDL/HDL) 
 
2.85±2.13 2.85±1.20 2.85±2.20 2.85±04.02 NS 
Albumin(g/dL) 
3.2±0.10 3.2±0.64 3.2±4.80 3.3±3.24 NS 
  
NS- Not Significant,**(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D 
(One way ANOVA followed by Dunnett’s test) 
Renal function test of Wistar albino rats group exposed to  
SWARNA PUSHPA RASA CHENDHURAM 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)* 
UREA (mg/dl) 22.11±0.10 22.10±0.15 22.16±1.22 22.12±1.63 N.S 
CREATININE(mg/dl
) 
0.6±0.02 0.6±0.03 0.6±0.05 0.6±0.09 N.S 
BUN(mg/dL) 27.5±0.03 27.5±0.14 27.8±0.30 27.8±1.40 NS 
URIC ACID(mg/dl) 6.04±0.02 6.1±0.20 6.1±0.30 6.2±0.60 N.S 
 
NS- Not Significant, **(p > 0.01), * (p >0.05) , n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test) 
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Liver Function Test of Wistar albino rats group exposed to  
SWARNA PUSHPA RASA CHENDHURAM 
PARAMETERS CONTROL LOW DOSE MID DOSE HIGH DOSE 
P Value 
(p)*  
T BILIRUBIN(mg/dl). 0.07±0.07 0.07±0.02 0.07±0.04 0.07±0.01 N.S 
SGOT/AST(U/L) 132.1±1.33 132.2±0.32 132.4±1.33 132.6±1.43 N.S 
SGPT/ALT(U/L) 99.10±1.44 99.14±1.10 99.24±1.64 99.23±0.20 N.S 
ALP(U/L) 182.40±1.12 182.2±1.14 183±1.24 184.3±2.51 N.S 
T.PROTEIN(g/dL) 6.5±0.13 6.5±0.21 6.7±0.32 6.7±0.34 N.S 
NS- Not Significant, **(p > 0.01), * (p >0.05), n = 10 values are mean ± S.D (One 
way ANOVA followed by Dunnett’s test 
HISTO PATHOLOGY 
CONTROL GROUP                        HIGH DOSE  
Kidney 
 
 
 
 
 
 
Liver 
 
 
  
Spleen 
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PRAMACOLOGICAL ACTIVITY 
ACTIVITY: ANTI PSORIATIC ACTIVITY 
CELL LINE MODEL: HUMAN KERATINOCYTE CELL LINES 
(HaCaT) 
       Control    6.25µg/ml                         12.5µg/ml 
  
 
  
 
 
 25µg/ml   50µg/ml   100µg/ml 
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LD 50 value – 40.3841 µg/ml 
OBSERVATION: 
LPS treatment produced effects similar to psoriasis as reported and the compound was 
effective in limiting the increased proliferation in HaCaT cells. 100ug/ml reduced the 
cell viability to 14.9% which is significant.  
Sample Concentration 
(µg/ml) 
Average 
Absorbance @ 
540nm 
Percentage 
Viability 
CONTROL 
(LPS stimulated) 
0.8581  
6.25 
0.81705 95.21617527 
12.5 
0.6576 76.63442489 
25 
0.4197 48.91038341 
50 
0.17865 20.81925184 
100 
0.1281 14.92833003 
 RESULTS AND OBSERVATION   99 
 
Results of the study were observed with respect to the following criteria 
1. Age distribution 
2. Gender distribution  
3. Occupational distribution 
4. Family history 
5. Socio economic status 
6. Diet 
7. Triggering factors 
8. Clinical features 
9. Associated clinical features 
10. Onset of disease 
OBSERVATIONS: 
 In the present clinical study, 60 patients of psoriasis were treated in the three 
groups completed the study plan. Following are the demographical observations made 
in this clinical study. 
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1. AGE DISTRIBUTION: 
 
S.NO AGE IN YEARS NO OF CASES 
(OUT OF 60) 
PERCENTAGE 
1.  18 to 30 14 23.4 
2.  31 to 40 15 25 
3.  41 to 50 20 33.3 
4.  51 to 60 11 18.3 
 
 
 
OBSERVATION: 
Among 60 cases, high age incidence (33.3%) is Between 41 – 50yr, low age incidence 
(18.3%) is Between 51 – 60yr. 
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2. GENDER DISTRIBUTION: 
 
S.NO SEX NO OF CASES 
(OUT OF 60) 
PERCENTAGE 
1.  Male  34 57 
2.  Female  26 43 
 
 
 
OBSERVATION: 
Among 60 patients, 34 patients (57%) were male, 26 patients (43%) were Female.  
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3. OCCUPATIONAL DISTRIBUTION: 
 
S.NO OCCUPATION 
NO OF CASES 
(OUT OF 60) 
PERCENTAGE 
1.  TAILOR          15 25 
2.  ENGINEER          6 10 
3.  LAB TECHNICIAN          10  16.7 
4.  HOME MAKER          5 8.3 
5.  TEACHER          3  5 
6.  PARLOUR WORKER          5  8.3 
7.  ELECTRICIAN          7  11.8 
8.  DRIVER          2 3.3 
9.  PHOTO GRAPHER          5 8.3 
10.  STUDENT          2 3.3 
 
 
 
OBSERVATION    
Among 60 patients, 15 Out of patients were tailor (25%), because due to 
mechanical stress.  
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4. FAMILY HISTORY: 
 
S.NO FAMILY HISTORY 
NO OF CASES  
(OUT OF 60) 
PERCENTAGE 
1.  Positive history 18 30 
2.  Negative history 42 70 
 
 
 
 
OBSERVATION: 
Among 60 patients only 18 patients (30%) were having positive family history.  
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5.   SOCIO ECONOMIC STATUS: 
 
S.NO 
SOCIO ECONOMIC 
STATUS 
NO OF CASES 
(OUT OF 60) 
PERCENTAGE 
1.  POOR  37 62% 
2.  MODERATE  17 28% 
3.  HIGHER  6 10% 
 
 
OBSERVATION:  
           Among 60 patients 37 patients were low income group (62%), 17 patients 
were middle Income group (28%), 6 patients were higher income group (10%).  
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6. DIET: 
 
S.NO DIET NO OF CASES (OUT OF 60) PERCENTAGE 
1.  Vegetarian  15 25 
2.  Mixed diet 45 75 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
Among 60 patients, 45 patients were non vegetarian (75%), 15 patients 
were vegetarian (25%). 
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7.TRIGERRING FACTORS: 
S. 
NO 
TRIGERRING 
FACTORS 
 
 
NO OF   
PATIENTS 
(OUT OF 60) 
PERCENTAGE 
% 
1  REACTION  TO  
DRUG   
CERTAIN 
 
          2        3.4%  
2  SKIN INJURY             4         6.6%  
3  PSYCHO-SOMATIC             1         1.6%  
4  ALCOHOL             10         16.6%  
5  SMOKING             5         8.4%  
6  NON VEGITARIAN             8          13.4%  
7 INFECTION             5         8.4%  
8 UNKNOWN            25          41.6%  
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
 Among 60 patients, 25 patients were unknown origin (41.6%), 8 patients were 
non vegetarian (13.4%),10 patients due to had alcohol (16.6%), 5 patients due to 
infection (8.4%), 5 patients due to had smoking as a factor (8.4%), 4 patients were 
skin injury (6.6%), 2 patients were Reaction to certain drug (3.4%), 1 patients were in 
Psycho somatic origin (1.6%) . 
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8.CLINICAL FEATURES: 
S.   
No  
CLINICAL FEATURE  BEFORE TREATMENT  AFTER TREATMENT  
NOOF  
PATIENTS  
PERCEN  
TAGE %  
NOOF  
PATIENTS  
PERCEN  
TAGE % 
1  ERYTHEMATOUS  
PATCHESWITHWHITE  
SILVERY SCALES  
60 100% 2 3.5% 
2  ITCHING  45 75% NIL 0% 
3  SCALP LESIONS  18 30% NIL 0% 
4  AUSPITZ SIGN  52 86.5% 2 3.5% 
5  CANDLEGREASE  
SIGN  
14 23.5% NIL 0% 
6  KOBNER’S  
PHENOMENON  
25 41.6% 3 5% 
7  NAIL CHANGES  8 13.5% 3 5% 
8  PALM  AND  SOLE  
LESIONS  
21 35% NIL 0% 
9  JOINT  
INVOLVEMENT.  
5 8.5%        1  2.5%  
 
 
 
 
 
 
 
 
 
 
OBSERVATION: 
 Among 60 patients have Erythematous patches with white silvery scales and 
Auspitz sign, Itching, Koebner’s phenomenon as their predominant symptoms in BT, 
but after treatment symptoms is fully reduced, nail and joint involvement mildly 
present.     
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9. ASSOCIATED CLINICAL FEATURES: 
 
S. No CLINICAL 
FEATURES 
NO OF 
PATIENTS 
PERCENTAGE 
% 
1  LOSS OF APPETITE  9 20% 
2  CONSTIPATION  7 12.5% 
3  INSOMNIA  25 57.5% 
4  ANAEMIA  21 52.5% 
5  HAIR FALL  17 30% 
 
 
 
OBSERVATION: 
Among 60 patients 7 had constipation,17 had hair fall,25 had sleep disturbances, 9  
had loss of appetite and 21 were anemic.  
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10. ONSET OF DISEASE: 
 
 
 
OBSERVATION: 
Among 60 patients, 21 had less than 1 yr (46.6%), 28 had 1-5year (35%), 11 had 
More than 5 years (18.4%).  
S. 
NO 
ONSET OF DISEASE 
 
NO OF  
PATIENTS 
(OUT OF 60) 
PERCENTAGE 
% 
1  LESS THAN 1YEAR  21 35 
2  1YEAR-5YEAR  28 46.6 
3  MORE THAN 5YEAR  11 18.4 
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GROUP I 
PASI SCORE FOR OPD PATIENTS TREATED WITH SWARNA PUSHPA 
RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) 
&PRANAYAMAN. 
S. 
NO 
OP. 
NO 
AGE/ 
SEX 
DOA DOD 
INITIAL 
PASI 
SCORE 
POST 
PASI 
SCORE 
SYMPTOMS 
REDUCED 
PER WEAK 
RESULT 
1  1283 49/F 16/06/16 25/07/16 16.2 4.0 7 Marked 
2  1162 30/F 09/08/16 21/09/16 31.8 4.6 6 Marked  
3  4228 58/F 14/07/16 26/08/16 19.4 4.1 6 Marked  
4  5002 44/F 18/07/16 03/09/16 4.8 1.0 7 Marked 
5  5104 39/F 18/07/16 16/08/16 22.8 6.8 4 Moderate 
6  4137 34/F 25/09/16 14/11/16 4.8 0 7 Marked  
7  1994 28/F 11/10/16 23/11/16 32.8 8.2 6 Marked 
8  8354 43/F 07/08/16 12/09/16 27.2 0 5 Marked  
9  5013 37/F 22/06/16 4/08/16 30.9 3.4 6 Marked 
10  2912 53/F 16/08/16 05/10/16 2.7 0.6 7 Marked  
11  9115 43/M 02/05/17 21/06/16 42.4 4.8 7 Marked  
12 4995 40/M 10/11/16 15/12/16 22.6 5.7 5 Moderate 
13  3365 42/M 12/07/16 01/08/16 27.3 2 7 Marked 
14 3435 26/M 12/07/16 03/08/16 12 8.3 3 Mild 
15  7638 24/M 27/07/16 09/09/16 14.4 0 6 Marked 
16  4986 30/M 18/07/16 23/08/16 20.2 7.4 5 Moderate 
17  5087 49/M 24/08/16 13/10/16 41.6 4.4 7 Marked  
18  1670 48/M 20/09/16 02/11/16 4.8 0 6 Marked  
19  3133 30/M 05/10/16 17/11/16 14 1.8 6 Marked 
20  7137 37/M 27/06/16 16/08/16 21.3 0 7 Marked 
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GROUP II 
PASI SCORE FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER 
THYLAM (EXT). 
S. 
NO 
OP. 
NO 
AGE/ 
SEX 
DOA DOD 
INITIAL 
PASI 
SCORE 
POST 
PASI 
SCORE 
SYMPTOMS 
REDUCED 
PER WEAK 
RESULT 
1  9658 25/M 08/08/16 20/09/16 14.4 0 6 Marked  
2  7894 42/M 11/08/16 30/09/16 21.6 5.2 7 Marked 
3  5612 36/M 15/0816 04/10/16 60 10.8 7 Marked  
4  3012 55/M 21/0816 03/10/16 15.6 0 6 Marked 
5  9632 45/M 23/08/16 11/09/16 13.6 5.4 4 Moderate 
6  5284 56/M 30/08/16 12/10/16 21 0 6 Marked 
7  1478 27/M 3/09/16 15/10/16 11.8 0.8 6 Marked  
8  4563 46/M 07/09/16 12/10/16 11.8 3.2 5 Moderate 
9  2354 52/M 14/0916 03/11/16 60 6.4 7 Marked  
10  6589 59/M 18/09/16 30/10/16 57 7.0 6 Marked 
11  1452 36/M 27/09/16 09/11/16 21.1 0.6 6 Marked  
12  6325 41/M 21/10/16 10/12/16 23.5 4.6 7 Marked 
13  7896 32/M 07/10/16 26/11/16 10.8 0 7 Marked  
14  7852 51/M 15/10/16 27/11/16 23.2 4.8 6 Marked 
15  2365 28/F 20/10/16 09/12/16 24.6 0 7 Marked  
16  2031 55/F 23/10/16 29/11/16 8.8 2.8 5 Moderate 
17  9630 59/F 28/10/16 30/11/16 21.3 0 6 Marked  
18  7456 25/F 09/11/16 07/12/16 14.4 6.4 4 Moderate 
19  2368 43/F 05/08/16 24/09/16 16.4 2.2 7 Marked  
20  3148 27/F 19/09/16 24/10/16 18.8 4.8 5 Moderate 
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                                                                    GROUP III 
PASI SCORE FOR OPD PATIENTS TREATED WITH  
VETTIVER THYLAM (EXT) &PRANAYAMAM 
S. 
N
O 
OP. 
NO 
AGE/ 
SEX 
DOA DOD 
INITIAL 
PASI 
SCORE 
POST 
PASI 
SCORE 
SYMPTOMS 
REDUCED 
PER WEAK 
RESULT 
1  5086 25/M 18/07/16 09/08/16 14.4 8 3 Mild 
2  5268 45/M 18/07/16 18/09/16 16.4 2.2 6 Marked  
3  9920 42/M 05/08/16 10/09/16 18.8 4.8 5 Moderate 
4  4570 57/M 22/08/16 11/10/16 16.2 4.0 7 Marked 
5  5460 49/M 20/07/16 02/09/16 31.8 4.6 6 Marked 
6  5171 45/M 18/07/16 03/09/16 19.4 4.1 7 Marked 
7  7369 31/M 26/07/16 08/09/16 4.8 1.0 6 Marked 
8  3107 42/M 21/06/16 26/07/16 22.8 6.8 5 Moderate 
9  3109 59/M 11/07/16 30/08/16 60 10.8 7 Marked 
10  2798 18/M 16/08/16 28/09/16 15.6 0 6 Marked 
11  1392 39/F 11/05/16 02/06/16 13.6 6.4 3 Mild 
12 2102 40/F 07/12/16 19/01/17 57 7.0 6 Marked 
13  769 38/F 06/09/16 25/10/16 21.1 0.6 7 Marked 
14  2580 50/F 08/07/16 27/08/16 23.5 4.6 7 Marked 
15  6566 22/F 28/06/16 10/08/16 10.8 0 6 Marked 
16  5931 36/F 05/07/16 24/08/16 23.2 4.8 7 Marked 
17  3124 50/F 09/07/16 21/08/16 21.3 0 6 Marked 
18  5469 33/F 15/07/16 27/08/16 42.4 4.8 6 Marked 
19  5224 45/F 21/07/16 26/08/16 22.6 5.7 5 Moderate 
20  3001 38/F 24/07/16 29/08/16 18.8 4.8 5 Moderate 
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CLINICAL IMPROVEMENT 
OP NO.7638       AGE : 24 / MALE 
 
 BEFORE TREATMENT        DURING TREATMENT 
 
 
 
 
 
 
 
 
 
 
 
AFTER TREATEMENT 
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OP NO. 5104       AGE : 39 / FEMALE 
 
BEFORE TREATMENT 
 
DURING TREATMENT 
 
 
 
 
 
 
AFTER TREATEMENT 
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 OP NO. 5460      AGE : 47 / MALE 
 
 
 
 
 
 
 
 
 
 
 
 
BEFORE TREATMENT    AFTER TREATEMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 BEFORE TREATMENT    AFTER TREATEMENT 
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OP NO. 4986       AGE : 30 / MALE 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BEFORE TREATMENT    AFTER TREATEMENT 
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CLINICAL IMPROVEMENT IN WEAK BASED ON 
PASI SCORE 
 
S.NO WEAKS OP PATIENTS PERCENTAGE% 
1 1WEAK NIL 0% 
2 2WEAK NIL 0% 
3 3 WEAK 3 5% 
4 4 WEAK 3 5% 
5 5 WEAK 10 16.6% 
6 6 WEAK 23 38.4% 
7 7 WEAK 21 35% 
 
 
OBSERVATION: 
           The clinical efficacy of SPRC was apparent from the PASI score at weak, 
Among the 60 patients, 3 patients (5%) had symptoms reduction in 3 weeks,                
3 patients (5%) had symptoms reduction in 4 weeks, 10 patients (16.6%)  had 
symptoms reduction in 5 weeks, 23 patients (38.4%) had symptoms reduction in          
6 weeks, 21 patients (35%) had symptoms reduction in 7weeks were noticed per 
week. 
 RESULTS AND OBSERVATION   121 
 PASI SCORE FOR OPD PATIENTS TREATED WITHSWARNA PUSHPA 
RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) 
&PRANAYAMAN.GROUP I 
S.No. OP No. 
PASI SCORE % of 
Reduction 
PASI BT AT 
1  
1283 16.2 4 75.3 
2  1162 31.8 4.6 85.5 
3  4228 19.4 4.1 78.8 
4  5002 4.8 1.0 79.1 
5  5104 22.8 6.8 70.2 
6  4137 4.8 0 100 
7  1994 32.8 8.2 75 
8  8354 27.2 0 100 
9  5013 30.9 3.4 88.9 
10  2912 2.7 0.6 77.7 
11  9115 42.4 4.8 88.6 
12 4995 22.6 5.7 74.7 
13  3365 27.3 2 92.6 
14  3435 12 8.3 30.8 
15  7638 14.4 0 100 
16  4986 20.2 7.4 63.3 
17  5087 41.6 4.4 89.4 
18  1670 4.8 0 100 
19  3133 14 1.8 87.1 
20  7137 21.3 0 100 
 
 RESULTS AND OBSERVATION   122 
CLINICAL IMPROVEMENT BASED ON PASI SCORE  
Criteria fixed to assess the clinical improvement was as follows,   
Marked improvement : PASI  ≥ 75%  
Moderate improvement : PASI 50% < 75%  
Mild improvement  : PASI 25 ≥ 50%  
Poor improvement  : PASI  > 25%   
CLINICAL IMPROVEMENT BASED ON PASI SCORE 
PATIENT TREATED WITH  INTERNAL& EXTERNAL MEDICINE & 
PRANAYAMAM 
S. 
NO 
EFFECT OF TRIAL 
MEDICINE 
NO OF 
PATIENTS 
PERCENTAGE 
% 
1  Marked improvement  
PASI  
16 80% 
2  Moderate improvement 
PASI < 75%  
3 15 % 
3  Mild improvement  
PASI ≥ 50%  
1 5% 
4  Poor improvement PASI 
> 25%  
NIL 0% 
                         TOTAL  20 100% 
 
 
 
 
 
 
 
 
 
OBSERVATION:  
                 Among 60 patients treated in OPD, out of 20 patients given internal drug, 
external drug &pranayamam, 16 out of 20 patients had marked improvement (80%), 3 
out of 20 patients had moderate improvement (15%), 1 out of 20 patients had mild 
improvement (5%). 
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PASI SCORE FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER 
THYLAM (EXT).GROUP II 
S.No. OP No. 
PASI SCORE % of 
Reduction 
PASI BT AT 
1  
9658 14.4 0 100 
2  7894 21.6 5.2 75.9 
3  5612 60 10.8 82 
4  3012 15.6 0 100 
5  9632 13.6 5.4 60.2 
6  5284 21 0 100 
7  1478 11.8 0.8 93.2 
8  4563 11.8 3.2 72.8 
9  2354 60 6.4 89.3 
10  6589 57 7.0 87 
11  1452 21.1 0.6 97.1 
12 6325 23.5 4.6 80.4 
13  7896 10.8 0 100 
14  7852 23.2 4.8 67.7 
15  2365 24.6 0 100 
16  2031 8.8 2.8 68 
17  9630 21.3 0 100 
18  7456 14.4 6.4 55.5 
19  2368 16.4 2.2 86.5 
20  3148 18.8 4.8 74.4 
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CLINICAL IMPROVEMENT BASED ON PASI SCORE 
PATIENT TREATED WITH  INTERNAL& EXTERNAL MEDICINE 
 
S. 
NO 
EFFECT OF TRIAL 
MEDICINE 
NO OF 
PATIENTS 
PERCENTAGE 
% 
1  Marked improvement  
PASI ≥ 75%  
      15          75%  
2  Moderate improvement 
PASI < 75%  
       5          25%  
3  Mild improvement  
PASI ≥ 50%  
      NIL          0%  
4  Poor improvement PASI 
> 25%  
      NIL           0%  
                         TOTAL         20            100%  
 
 
 
OBSERVATION:  
                 Among 60 patients treated in OPD, out of 20 patients given internal drug, 
external drug, 15out of 20 patients had marked improvement (75%), 5 out of 20 
patients had moderate improvement (25%) . 
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PASI SCORE FOR OPD PATIENTS TREATED WITH  
VETTIVER THYLAM (EXT) &PRANAYAMAMGROUP III 
S.No. OP No. 
PASI SCORE % of 
Reduction 
PASI BT AT 
1  
5086 14.4 8 44.4 
2  5268 16.4 2.2 86.5 
3  9920 18.8 4.8 74.4 
4  4570 16.2 4.0 75.3 
5  5460 31.8 4.6 85.5 
6  5171 19.4 4.1 78.8 
7  7369 4.8 1.0 79.16 
8  3107 22.8 6.8 70.1 
9  3109 60 10.8 82 
10  2798 15.6 0 100 
11  1392 13.6 6.4 60.2 
12 2102 57 7 87.7 
13  769 21.1 0.6 97 
14  2580 23.5 4.6 80.4 
15  6566 108. 0 100 
16  5931 23.2 4.8 79.3 
17  3124 21.3 0 100 
18  5469 42.4 4.8 88.6 
19  5224 22.6 5.7 74.7 
20  3001 18.8 4.8 74.4 
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CLINICAL IMPROVEMENT BASED ON PASI SCORE 
PATIENT TREATED WITH  EXTERNAL MEDICINE & PRANAYAMAM 
 
S. 
NO 
EFFECT OF TRIAL 
MEDICINE 
NO OF 
PATIENTS 
PERCENTAGE 
% 
1  Marked improvement  
PASI ≥ 75%  
14 70% 
2  Moderate improvement 
PASI < 75%  
4 20 % 
3  Mild improvement  
PASI ≥ 50%  
2 10% 
4  Poor improvement PASI 
> 25%  
NIL 0% 
                         TOTAL  20 100% 
 
 
 
OBSERVATION:  
                 Among 60 patients treated in OPD, out of 20 patients given external drug 
&pranayamam, 14 out of 20 patients had marked improvement (80%), 4 out of 20 
patients had moderate improvement (15%), 2 out of 20 patients had mild 
improvement (5%).  
 RESULTS AND OBSERVATION   127 
COMPARISON IN EFFECT OF TRIAL MEDICINE  
GROUP I, II & III ON PASI SCORE 
S. 
NO. 
EFFECT OF 
TRIAL 
MEDICINE 
NO OF 
PATIENTS 
GROUP I 
NO. OF 
PATIENTS 
GROUP II 
NO. OF 
PATIENTS 
GROUP III 
% OF THE 
PASI 
SCORE 
1. Marked 
improvement 
PASI ≥ 75% 
16 15 14 75 
2. Moderate 
improvement 
PASI < 75% 
3 5 4 20 
3. Mild 
improvement 
PASI ≥ 50% 
1 0 2 5 
4. Poor 
improvement 
PASI > 25% 
0 0 0 0 
 
COMPAIRSON IN EFFECT OF TRIAL MEDICINE  GROUP I, II 
& III ON PASI SCORE
0
10
20
30
40
50
60
70
80
NO OF
PATIENTS
GROUP I
NO. OF
PATIENTS
GROUP II
NO. OF
PATIENTS
GROUP III
% OF THE
PASI
SCORE
Marked improvement PASI
> 75%
Moderate improvement
PASI < 75%
Mild improvement PASI >
50%
Poor improvement PASI >
25%
 
 
OBSERVATION:  
                 Among 60 patients treated in OPD, 45 patients had marked improvement 
(75%), 12 patients had moderate improvement (20%), 3 patients had mild 
improvement (5%). 
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6. DISCUSSION 
 Thadippu Perunoi (psoriasis) is  a chronic, inflammatory and proliferative skin 
disease with scaling and itching.  Thadippu Perunoi is non-contagious disease, 
erythematous, silvery scales are characteristic social stigma. It can leads to 
discrimination, making a negative remarks about mental illness, stress, etc. 
 
        The trail drugs were prepared by the Author in the Gunapadam practical 
laboratory of Government Siddha Medical Collage, after getting proper authentication 
of raw drugs from the Medicinal Botany Department under the supervision of the 
members of the teaching faculty and guided by the Head of the Department of Sirappu 
Maruthuvam of the Government Siddha Medical College, Chennai-106. 
 
 In clinical study, 60 patients were selected, 20 patients were  treated internal 
medicine, external oil and Pranayamam,20 patients were treated with internal 
medicine and external oil ,20 patients were treated with external oil and Pranayamam. 
Patients were treated in the out-patient department of Sirappu Maruthuvam 
 
TRAIL DRUGS: 
 INTERNAL MEDICINE: Swarna Pushpa Rasa Chendhuram 
EXTERNAL MEDICINE: Vettiver Thylam 
    Pranayamam 
 
 Based on various criteria, the data were collected and tabulated .  The criteria 
were distribution of age, gender, occupation, family history, diet, clinical 
manifestations and assessment of the improvement in the prognosis of the disease 
with trail drugs. 
 
 
1.    AGE DISTRIBUTION  : 
 Among 60 cases, high age incidence (33.3%) is Between 41 – 50yr,  low age 
incidence (18.3%) is Between 51 – 60yr.  Thadippu Perunoi can appear at birth as 
well as very old age. In this present study, considerable numbers of patients were 
reported between the age of 41-50yrs among study sample. 
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2. GENDER DISTRIBUTION  : 
 Among 60 patients, 34 patients (57%) were male, 26patients (43%) were 
Female. Generally Thadippu Perunoi occurs with almost equal frequency in males 
and females, but a slightly more number of female cases were reported. 
 
3. OCCUPATIONAL DISTRIBUTION  : 
 Among 60 patients, 15 Out of patients were tailor (25%), because due to 
mechanical stress.  
 
4.    FAMILY HISTORY: 
Among 60 patients only 18 patients (30%) were having positive family 
history. 
 
5.    SOCIO ECONOMIC STATUS: 
 Among 60 patients 37 patients were low income group (62%), 17 patients 
were middle Income group (28%), 6 patients were higher income group (10%). 
 
6.     DIET: 
 Among 60 patients, 45 patients were non vegetarian (75%), 15 patients were 
vegetarian (25%). 
 
7.   TRIGERRING FACTORS: 
 Among 60 patients, 25 patients were unknown origin (41.6%), 8 patients were 
non vegetarian (13.4%),10 patients due to had alcohol (16.6%), 5 patients due to 
infection (8.4%), 5 patients due to had smoking as a factor (8.4%), 4 patients were 
skin injury (6.6%), 2 patients were Reaction to certain drug (3.4%), 1 patients 
were in Psycho somatic origin (1.6%) . 
 
8.CLINICAL FEATURES: 
      Among 60 patients have Erythematous patches with white silvery scales and 
Auspitz sign, Itching, Koebner’s phenomenon as their predominant symptoms in 
BT, but after treatment symptoms is fully reduced, nail and joint involvement 
mildly present.     
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9.CLINICAL IMPROVEMENT IN WEAK BASED ON PASI SCORE 
 The clinical efficacy of SPRC was apparent from the PASI score at weak, 
Among the 60 patients,3 patients (5%) had symptoms reduction in 3 weeks, 3 patients 
(5%) had symptoms reduction in 4 weeks, 10 patients (16.6%) had symptoms 
reduction in 5 weeks, 23 patients (38.4%) had symptoms reduction in 6 weeks,           
21 patients (35%) had symptoms reduction in 7 weeks were noticed per week. 
 
10. CLINICAL IMPROVEMENT BASED ON PASI SCORE PATIENT 
TREATED WITH INTERNAL& EXTERNAL MEDICINE &PRANAYAMAM 
                 Among 60 patients treated in OPD, out of 20 patients given internal drug, 
external Drug & Pranayamam, 16 out of 20 patients had marked improvement (80%), 
3 out of 20 patients had moderate improvement (15%), 1 out of 20 patients had mild 
improvement (5%).  
 
11.  CLINICAL IMPROVEMENT BASED ON PASI SCORE PATIENT 
TREATED WITH  INTERNAL& EXTERNAL MEDICINE  
              Among 60 patients treated in OPD, out of 20 patients given internal drug, 
external drug, 15out of 20 patients had marked improvement (75%), 5 out of 20 
patients had moderate improvement (25%). 
 
12. CLINICAL IMPROVEMENT BASED ON PASI SCORE PATIENT 
TREATED WITH  EXTERNAL MEDICINE & PRANAYAMAM 
 
               Among 60 patients treated in OPD, out of 20 patients given external drug & 
Pranayamam, 14out of 20 patients had marked improvement (80%), 4 out of 20 
patients had moderate improvement (15%), 2 out of 20 patients had mild 
improvement (5%).  
 
13. STATISTICAL RESULTS 
 Since the p value is significant in all clinical features.  So there is significant 
reducing of clinical features among the patients for the treatment of psoriasis.  
Hence it is concluded that the treatment was effective and significant. 
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 Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment (internal 
medicine, external medicine & Pranayamam) of Thadippu Perunoi 
(psoriasis).Hence it is concluded that the treatment was effective and 
significant. 
 
 Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment (internal 
medicine & external medicine) of Thadippu Perunoi (psoriasis).Hence it is 
concluded that the treatment was effective and significant. 
 
 Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment (external 
medicine & Pranayamam) of Thadippu Perunoi (Psoriasis).Hence it is 
concluded that the treatment was effective and significant. 
 
 
The outcome of the study was clinically observed by PASI Score. Which showed 
encouraging results of marked improvement in 45 patients (75%), moderate 
improvement in 12 patients (20%),  and mild improvement in 3 patients (5%). 
 
MARKED IMPROVEMENT  - 75% 
MODERATE IMPROVEMENT - 20% 
MILD IMPROVEMENT - 5 % 
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7. SUMMARY 
AN OPEN COMPARATIVE CLINICAL EVALUATION ON 
“THADIPPU PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL 
DRUGS “SWARNA PUSHPA RASA CHENDHURAM” (INT), 
“VETTIVER THAILAM (EXT)’’ AND “PRANAYAMAM” has been 
chosen for the dissertation work by the author. 
 The aim of the study was to evaluate the safety and efficacy of Herbo metallic 
Siddha Drugs “Swarna Pushpa Rasa Chendhuram” (Int), “Vettiver 
Thailam (Ext)’’ and “Pranayamam” in management of Thadippu Perunoi 
(Psoriasis). 
 Literatures evidence have been collected from siddha and modern textbooks 
and also the drug review also said. 
 Standared operative procedure for both trial drugs was standardized. 
 Pre - clinical toxicity study was done for the trial drug “Swarna Pushpa Rasa 
Chendhuram” (Int), in using of female Wister albino rats. Toxicity study 
was carried out after getting proper permission in Institutional Animal Ethical 
Committee (IAEC). 
 The study is conducted after the drug being screened by the screening 
committee and the trial is also approved by the Institutional Ethical Committee 
(IEC). The clinical trial also registered in Clinical Trial Registry of India 
(CTRI). 
 Qualitative and Quantitative study on the trial drug such as Physico-chemical 
analysis, had been done, results are normal in range. 
 Anti-Psoriatic activity of “Swarna Pushpa Rasa Chendhuram” (Int), was 
studied in Human Keratinocytes cell line (HaCaT) in vitro method. 
 60 Patients of both sex and in agegroupbetween 18-60 years were selected for 
this clinical trial. 
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 Among 60 patients were from OPD, 20 Patients were selected for treating with 
both trial drugs Internal, External & Pranayamam, 20 patients were treated 
with internal drug and external drug, 20 patients were treated with external 
drug & Pranayamam. 
 All the details about this study and the trial drug SPRCconsent forms duly 
signed by them, separate proforma was maintained for each patients. 
 Photos of the patient before and after treatment for the evidence of clinical 
improvement. 
 Before and after treatment blood samples are collected for the laboratory 
investigation. 
 The safety of the trial drug SWARNA PUSHPA RASA CHENDHURAM was 
assessed by comparing the safety parameters such as LFT AND RFT before 
and after treatment was taken. 
 From the first day onwards SWARNA PUSHPA RASA CHENDHURAM, 
65Mg twise daily was given internally and VETTIVER THYLAM  - 100ml 
for external application & PRANAYAMAM given to the patients. 
 Clinical improvement was assessed using of PASI SCORE. 
 Among 60 patients, out of 20 patients given internal drug, external drug 
&pranayamam,16out of 20patients had marked improvement (80%),3 out of 
20 patients had moderate improvement(15%) ,1 out of 20 patients had mild 
improvement (5%) out of 20 patients given internal drug, external drug,15out 
of 20patients had marked improvement (75%),5 out of 20 patients had 
moderate improvement (25%) out of 20 patients given external drug 
&pranayamam,14out of 20patients had marked improvement (80%),4out of 20 
patients had moderate improvement(15%),2 out of 20 patients had mild 
improvement (5%).  
 Finally statistical analysis was performed to assess the significance of 
theclinical trial. 
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 Since the p value is significant in all clinical features.  So there is significant 
reducing of clinical features among the patients for the treatment of Thadippu 
Perunoi (psoriasis).Hence it is concluded that the treatment was effective and 
significant. 
 Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment (internal 
medicine, external medicine & Pranayamam) of Thadippu Perunoi 
(psoriasis).Hence it is concluded that the treatment was effective and 
significant. 
 Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment (internal 
medicine & external medicine) of Thadippu Perunoi (psoriasis).Hence it is 
concluded that the treatment was effective and significant. 
 Since the P value is highly significant (<0.001). So there is significant 
reducing of PASI Score among the patients for the treatment (external 
medicine & Pranayamam) of Thadippu Perunoi (Psoriasis).Hence it is 
concluded that the treatment was effective and significant. 
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8.   CONCLUSION 
 Heavy metal analysis of Swarna Pushpa Rasa Chendhuram (SPRC) reveals that 
the drug does not contain any metals like lead, Cadmium, Arsenic and mercury. 
 Acute and sub- acute toxicity study reveals that the trial drug Swarna Pushpa Rasa 
Chendhuram considered as safe. 
 Anti-Psoriatic activity of Swarna Pushpa Rasa Chendhuram was studied in 
Human Keratinocytes cell line (HaCaT),   LPS treatment produced effects similar 
to psoriasis as reported and the compound was effective in limiting the increased 
proliferation in HaCaT cells. 100ug/ml reduced the cell viability to 14.9% which 
is significant.  
 Among 60 patients treated in OPD, 45 patients had marked improvement (75%), 
12 patients had moderate improvement (20%), 3 patients had mild improvement 
(5%). Result of the study was concluded by reducing PASI SCORE. 
 Pranayamam may have treating ability of psoriasis by reducing stress. And it is 
along with the Siddha trial drugs was very effective in overall improvements were 
good.  And itching and scaling was reduced in group I and III are very effective 
when comparing to group I. 
 The LFT & RFT before and after treatment does not show any significant change 
in psoriasis cases, hence it is safe in human trial.   In my clinical trial during the 
course of the trial were no adverse effect or unwanted drug reactions in GIT, RS, 
CVS & excretory system. 
  The results of the clinical trial indicate that the trial drug Swarna Pushpa Rasa 
Chendhuram (Internal) Vettiver Thylam (External) and Pranayamam are clinically 
more effective in THADIPPU PERUNOI (PSORIASIS) Patients.  
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AN OPEN COMPARATIVE CLINICAL EVALUATION ON “THADIPPU
PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL DRUGS “SWARNA
PUSHPA RASA CHENDHURAM” (INT), “VETTIVER THAILAM (EXT)’’
AND “PRANAYAMAM”.
FORM l - SCREENING & SELECTION PROFORMA
1. OP NO                  : ……………………………
2. NAME                  : ………………………………………….
3. AGE                      : ………
4. GENDER : ………….......
5. OCCUPATION   : ………………………………..
6. INCOME             : ………………
7. ADDRESS           : …………………………………………………….
…………………………………………………….
…………………………………………………….
                                    …………………………………….........................
8. CONTACT NO   : ……………………………………
INCLUSION CRITERIA
 Age :15-60 years    Yes / No
 Sex : Both male and female Yes / No
 Patches with Scaling    Yes / No
 Auspitz sign +    Yes/ No
 Koebner’s phenomenon +    Yes/No
 Patients Willing to fill consent form Yes/ No
 Patients willing to take photograph before& after treatment                       Yes / No
EXCLUSION CRITERIA:
 HISTORY OFAlcohol
  Narcotic addicts
 Anti –malarial drugs
  Cardiac disease
  Leprosy
  Peptic ulcer
  SLE, Progressive systemic sclerosis
  Evidences of secondary infection in the lesions
  Pregnancy and lactation
  HIV
 Syphilis
  Long term intake of steroids
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FORM II - HISTORY TAKING PROFORMA ON ENROLLMENT
1.SERIAL NO OF THE CASE: …………………
2.OP  NO: ......................................
3. NAME: ……………………………  4.AGE: …………       5.GENDER:
.................
6. MARITAL STATUS 1.Married 2.Unmarried
7. COMPLAINTS & DURATION:
8. CHIEF COMPLAINTS WITH DURATION
Present Absent Duration (indays)
1.Itching :
2. Dryness of the skin :
3. Roughness :
4. Circular erythema :
5. Exfoliation :
6. Hyper Pigmentation :
7. Hypo-Pigmentation :
8. Maceration :
9. Pin point bleeding
After removal of skin :
10. Papule/Pustule/Vesicle :
11. Fissures :
9. HISTORY OF PRESENT ILLNESS
1. Onset of disease : Acute Insidious
2. Duration of disease :
3. Treatment given so far : Ayurvedic medicine Modern
Medicine
Unani
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10. PERSONAL HISTORY:
         PERSONAL HABITS YES NO IF YES
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DURATION
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           Any Habit of Narcotic  Drug Addiction
11. DRUG HISTORY:
12. FAMILY HISTORY:
Whether this problem runs in family?
1. Yes                               2.No
If yes, mention the relationship of affected person(s) ---------------------
History of previous investigations if any ------------------------------
13. DIETARY STYLE:
 1. Pure vegetarian
2. Non-vegetarian
14. BOWEL HABITS & MICTURITION:
15. MENSTURAL AND OBSTETRIC HISTORY:
16. HISTORY OF PREVIOUS ILLNESS/PELVIC SURGERY
Date: Signature of the guide
Station:
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FORM III - CLINICAL ASSESSMENT ON ENROLLMENT PROFOMA
1. OP NO:------------
2. NAME: ----------------------        3. AGE: ---------              4.GENDER: ----------
5. DATE OF BIRTH:
            D    M Y   E   A   R
 6. DATE OF INITIAL ASSESSMENT: ----------------------
 SIDDHA SYSTEM OF EXAMINATION:
1. THEGI (BODY CONSTITUTION):
1. Vatha udal
2. Pitha udal
3. Kaba udal
4. Thontha udal
2. NILAM (LAND WHERE THE PATIENT LIVED MOST):
1. Kurinji
2. Mullai
3. Marutham
4. Neithal
5. Paalai
3. KAALAM:
1. Kaar kaalam (Aavani-Puratasi)
2. Koothir kaalam (Ippasi-Kaarthigai)
3. Munpani kaalam (Maargazhi-Tai)
4. Pinpani kaalam (Maasi-Panguni)
5. Ilavenil kaalam (Chithirai-Vaigasi)
6. Muthuvenil kaalam    (Aani-Aadi)
4. GUNAM:
1. Sathuvam
2. Rasatham
3. Thamasam
5. PORIPULANGAL (SENSORY ORGANS):
NormalAffected
1. Mei ..............................................................................
2. Vaai   (Naaku)
..............................................................................
3. Kan
..............................................................................
4. Mookku
..............................................................................
5. Sevi
..............................................................................
6. KANMENDRIYAM (MOTOR ORGANS) :
NormalAffected
1. Vaai
..............................................................................
2. Kaal
..............................................................................
3. Kai
..............................................................................
4. Eruvaai
..............................................................................
5. Karuvaai
..............................................................................
7. KOSANGAL (SHEATH):
NormalAffected
1. Annamaya kosam .      ....
..................................................................
2. Pranamaya kosam...................................................................
3. Manomaya kosam................. . . . ............................................
4. Vignanamaya kosam     ....................................................................
5. Anandhamaya kosam     .....................................................................
8. UYIR THATHUKKAL (THREE HUMOURS):
8a.VALI: Normal   Affected
1. Praanan
..............................................................................
2. Abaanan
..............................................................................
3. Viyaanan
..............................................................................
4. Uthaanan
..............................................................................
5. Samaanan
..............................................................................
6. Naagan
..............................................................................
7. Koorman
..............................................................................
8. Kirukaran
..............................................................................
9. Devathathan
..............................................................................
10. Dhananjayan .
.............................................................................
8b. AZHAL:              Normal    Affected
1. Analam
..............................................................................
2. Ranjagam
..............................................................................
3. Saathagam
..............................................................................
4. Aalosagam
..............................................................................
5. Praasagam
.............................................................................
8c.IYAM:  Normal    Affected
1. Avalambagam
..............................................................................
2. Kilethagam
..............................................................................
3. Pothagam
..............................................................................
4. Tharpagam
..............................................................................
5. Santhigam
..............................................................................
9. EN VAGAI THERVU (EIGHT FOLDS OF EXAMINATION):
1.Naadi:  ……………………….................
2.Parisam:           ……………………….................
3.Naa         :           ............………………..................
4.Niram     :           .....…………………….................
5.Mozhi:      .....…………………….................
6.Vizhi       :           ......................................................
7.Malam    :           .....................................................
8. Moothiram:      ………………………………….
         8a.Neerkuri:
Niram      : 1.Whitish                             2. Yellowish
3.Straw coloured 4. Crystal clear
Edai: 1.Present 2.Absent
Manam    : 1.Nil                     2.Reduced                    3. Increased
Nurai: 1. Normal             2. Increased                  3. Decreased
Enjal:
 8b: Neerkuri (Oil –in urine sign):
Vatha Neer Pitha Neer Kaba Neer
10. SEVEN UDAL THAATHUKKAL (SEVEN SOMATIC COMPONENTS):
NormalAffected
1. Saaram
..................................................................
2. Senneer ..
..........................................................
3. Oon
..................................................................
4. Kozhuppu
..................................................................
5. Enbu
..................................................................
6.Moolai
..................................................................
7. Sukkilam / Suronitham
..................................................................
GENERAL EXAMINATION:
1. Body weight [Kg] :
2. Height [cm] :
3. Body Temperature [F] :
4. Blood Pressure (mmHg) :
5. Pulse Rate /min. :
6. Heart Rate / min. :
7. Respiratory Rate /min. :
Yes No
8. Pallor :
9. Jaundice :
10. Clubbing :
11. Cyanosis :
12. Pedal Oedema :
13. Lymphadenopathy        :
14. Jugular venous pulsation  :
VITAL ORGAN EXAMINATION:
Normal          Abnormal
1.  Heart
2. Lungs
3. Brain
4. Liver
5. Kidney
6. Spleen
7. Stomach
SYSTEMIC EXAMINATION:
Normal          Abnormal
1. Cardio-vascular system
2. Respiratory system
3. Gastro intestinal system
4. Central nervous system
5. Genital urinary system
6.  Endocrine system
11. CLINICAL EXAMINATION:
CLINICAL EXAMINATION OF SKIN
1.Site: ---------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------
---------------------------
2. Colour: Normal          Reddish     Black              Greyish
3. Shape: Irregular Coin shape D           dispersed
4. Itching: No        Mild   Moderate Severe
5. Scaling: Mild                      Moderate                 Severe
6. Erythema:       Present Absent
7. Bleeding: Present Absent
8. Crusting:       Present Absent
9. Lichenification:                               Present Absent
10. Oozing:         No             Mild                  Moderate          severe
11. Auspitz sign: Present Absent
12. Koebner’s phenomenon: Present Absent
13. Candle grease sign: Present Absent
YES NO
 14. Ulcération:
 15. Macule:
 16. Papule:
 17. Pustule:
       18. Blister:
 19. Vesicle:
 20. Pigmentation: Normal  Hypo                       Hyper
EXAMINATION OF NAILS:
1.  Pitting: Present Absent
2   Thickening: Present Absent
3.  Collection of Hyperkeratotic debris: Present Absent
4.  Separation of distal portion of nail: Present Absent
EXAMINATION OF JOINTS:
  YES                             NO
Joint Involvement
PASI SCORE ASSESSMENT
Pasi
score
0 day 7th 14th 21st 28th 35th 42nd 49th
PSORIASIS AREA AND SEVERITY INDEX (PASI)
E – Erythema D – Desquamation
 I – Infiltration A – Area
PASI=0.1(EH+IH+DH) AH+0.2 (EU+IU+DU) AU+0.3 (ET+IT+DT) AT+0.4 (EL+IL+DL)AL
Erythema/ Infiltration/Desquamation scoring                                  Area Scoring
0 - Nil 0-Nil
1- Mild 1-Less than 10%
2- Moderate       2- 11%-30%
3-Severe       3-31%-50%
4-Very high 4-51%-70%
5-71%-90%
6-91%-100%
                               PASI Calculation
Patient name
Date
Body region and weighting factor
Plaque Characteristic Rating Score Head UpperLimbs Trunk
Lower
Limbs
Erythema 0 = None
1 = Slight
Thickness
2 = Moderate
3 = Severe
Scaling
4 = Very Severe
      Totals
Weighting Factor     x 0.1    x 0.2   x 0.3    x 0.4
Surface area totals
0 = None
1 = 1-10%
2 = 11-30%
3 = 31-50%
Degree of involvement as
% for each body region
affected (score each
region between 0 and 6) 4 = 51-70%
5 = 71-90%
6 = 91-100%
Surface area totals x %
involvement totals
Sum Scores above =
REF: PSORIASIS GLOBAL ASSSESSMENT LATTICE  SYSTEM PHYSICIAN GLOBAL ASSESSMENT
Date     :
Station:                                                                         Signature of the guide:
                                                                                        Signature of the Investigator:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
                                                       CHENNAI – 600 106
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
PRINICIPAL INVESTIGATOR: Dr. A. Anitha                            REG NO:
AN OPEN COMPARATIVE CLINICAL EVALUATION ON “THADIPPU
PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL DRUGS “SWARNA
PUSHPA RASA CHENDHURAM” (INT), “VETTIVER THAILAM (EXT)’’
AND “PRANAYAMAM”.
FORM IV: LABORATORY INVESTIGATIONS PROFORMA
1. SERIAL NO OF THE CASE: …………………
2.OP  NO: ......................................
3. NAME: ……………………………   4.AGE: ……     5.GENDER: .................
A) BLOOD INVESTIGATIONS
BLOOD INVESTIGATIONS NORMALVALUES
BEFORE
TMT (WITH
DATE)
AFTER TMT
(WITH DATE)
HB( gm/dl)
M:12-15
W:11.5-14
T.WBC (cells/cu.mm) 4000-11000
Polymorphs 40-75
Lymphocytes 20-40
Monocytes 2-10
Eosinophils 1-6
DIFFERENTIAL
COUNT (%)
Basophils 0-1
T.RBC(million cells/cu.mm)
M:4.0-5.5
W:3.5-4.5
  ESR(mm/hour) ½ hr.
1 hr.
M:6-12
W:7-18
Blood Investigations Normal Values
Before
TMT(WITH
DATE)
After TMT
(WITH DATE)
Fasting    70-110
PP    80-140Bloodglucose
(mg/dl)
Random    80-120
Blood urea    16-50
RFT
(mg/dl)
Serum creatinine    0.6-1.2
Total bilirubin    0.2-1.2
Direct bilirubin    0.1-1.2
Indirect
bilirubin    0.2-0.7
SGOT    0-40
SGPT    0-35
LFT
(mg/dl)
Alkaline
phosphatase    80-290
B) URINE INVESTIGATIONS:
URINE
INVESTIGATIONS
BEFORE TREATMENT AFTER TREATMENT
Albumin
          Sugar
Deposits
Date:
Station:
                              Signature of the Guide
                                                                                    Signature of the Investigator
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
PRINICIPAL INVESTIGATOR: Dr.A. Anitha  REG NO:
AN OPEN COMPARATIVE CLINICAL EVALUATION ON “THADIPPU
PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL DRUGS “SWARNA
PUSHPA RASA CHENDHURAM” (INT), “VETTIVER THAILAM (EXT)’’
AND “PRANAYAMAM”.
FORM V: INFORMED CONSENT FORM
“I have read the foregoing information, or it has been read to me. I have
had the opportunity to ask questions about it and any questions I have asked have
been answered to my satisfaction.
I   consent voluntarily to participate in this study and understand that I have
the   right to withdraw from the study at any time without in any way it affecting my
further medical care”.
"I have received a copy of the information sheet/consent form".
Date:
Signature of the participant:
In case of illiterate participant
 “I have witnessed the accurate reading of the consent form to the potential
participant, and the individual has had the opportunity to ask questions. I confirm
that the individual has given consent freely.”
Date:
Signature of a witness                           Left thumb Impression of the Participant
(Selected by the participant bearing no connection with the survey team)
Date:
Station:
Signature of participant:
Signature of the Guide
                                                            Signature of the Investigator
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢,
«È¢»÷ «ñ½¡ ÁÕòÐÅÁ¨É, ¦ºý¨É-106
jbg;G ngUNeha; §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý ெசௗ ண பரச ெச ர ,
ெவ ேவ ைதல ம ராணயாம
À¡¢¸¡¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ.
´ôÒ¾ø ÀÊÅõ
¬öÅ¡ÇÃ¡ø º¡ýÈÇ¢ì¸ôÀð¼Ð
¿¡ý þó¾ ¬ö¨Å ÌÈ¢ò¾ «¨ÉòÐ Å¢ÀÃí¸¨ÇÔõ §¿¡Â¡Ç¢ìÌ ÒÃ¢Ôõ
Å¨¸Â¢ø ±ÎòÐ¨Ãò§¾ý ±É ¯Ú¾¢ÂÇ¢ì¸¢§Èý.
§¾¾¢: ¨¸¦Â¡ôÀõ:
þ¼õ: ¦ÀÂ÷    :
§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø
±ýÉ¢¼õ þó¾ ÁÕòÐÅ ¬öÅ¢ý ¸¡Ã½ò¨¾Ôõ, ÁÕó¾¢ý ¾ý¨Á ÁüÚõ
ÁÕòÐÅ ÅÆ¢Ó¨È ÀüÈ¢Ôõ, ¦¾¡¼÷óÐ ±ÉÐ ¯¼ø þÂì¸ò¨¾ ¸ñ¸¡½¢ì¸×õ,
«¾¨É À¡Ð¸¡ì¸×õ ÀÂýÀÎõ ÁÕòÐÅ ¬ö×ìÜ¼ ÀÃ¢§º¡¾¨É¸û ÀüÈ¢ ¾¢Õô¾¢
«Ç¢ìÌõ Å¨¸Â¢ø ¬ö× ÁÕòÐÅÃ¡ø Å¢Çì¸¢ì ÜÈôÀð¼Ð.
¿¡ý þó¾ ÁÕòÐÅ ¬öÅ¢ý §À¡Ð, ¸¡Ã½õ ±Ð×õ ÜÈ¡Áø, ±ô¦À¡ØÐ
§ÅñÎÁ¡É¡Öõ  þó¾ ¬öÅ¢Ä¢ÕóÐ   ±ý¨É Å¢ÎÅ¢òÐ ¦¸¡ûÙõ
¯Ã¢¨Á¨Â ¦¾Ã¢ó¾¢Õì¸¢ý§Èý.  ¿¡ý ±ýÛ¨¼Â Í¾ó¾¢ÃÁ¡¸ §¾÷× ¦ºöÔõ
¯Ã¢¨Á¨Âì ¦¸¡ñÎ jbg;G ngUNeha; §¿¡öì¸¡É ெசௗ ண ப ரச
ெச ர ,ெவ ேவ ைதல ம ராணயாம ஆகியவ றி
ÀÃ¢¸Ã¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢üÌ ±ý¨É ¯ðÀÎò¾ ´ôÒ¾ø
«Ç¢ì¸¢§Èý.
இ ம க னா ஏ ப ப க ைள க றி
வ க ப ள .
§¾¾¢: ¨¸¦Â¡ôÀõ:
þ¼õ: ¦ÀÂ÷          :
§¾¾¢: º¡ðº¢ì¸¡Ã÷ ¨¸¦Â¡ôÀõ:
þ¼õ: ¦ÀÂ÷   :
¯È×Ó¨È :
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
PRINICIPAL INVESTIGATOR: Dr. A.Anitha                            REG NO:
AN OPEN COMPARATIVE CLINICAL EVALUATION ON “THADIPPU
PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL DRUGS “SWARNA
PUSHPA RASA CHENDHURAM” (INT), “VETTIVER THAILAM (EXT)’’
AND “PRANAYAMAM”.
FORM VI - WITHDRAWAL FORM
SERIAL NO OF THE CASE:  OP NO:
 NAME:  AGE/GENDER:
 DATE OF TRIAL COMMENCEMENT:
DATE OF WITHDRAWAL FROM TRIAL:
 REASONS FOR WITHDRAWAL:
Long absence at reporting: Yes/ No
Irregular treatment: Yes/ No
Shift of locality: Yes/No
Increase in severity of symptoms: Yes/No
Development of severe adverse drug reactions: Yes/No
Development of adverse event: Yes/No
Date:
Station:
Signature of the Investigator: Signature of the Guide:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
PRINICIPAL INVESTIGATOR: Dr. A.Anitha REG NO:
AN OPEN COMPARATIVE CLINICAL EVALUATION ON “THADIPPU
PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL DRUGS “SWARNA
PUSHPA RASA CHENDHURAM” (INT), “VETTIVER THAILAM (EXT)’’
AND “PRANAYAMAM”.
FORM VII- (DRUG COMPLIANCE FORM)
STUDYNO: OP NO:
NAME:                   AGE/GENDER:
DRUG NAME: SWARNA PUSHPA RASA CHENTHURAM
Day Date Morning Evening Day Date Morning Evening
Day 1 Day25
Day2 Day26
Day3 Day27
Day4 Day28
Day5 Day29
Day6 Day30
Day7 Day31
Day8 Day32
Day9 Day33
Day10 Day34
Day11 Day35
Day12 Day36
Day13 Day37
Day14 Day38
Day15 Day39
Day16 Day40
Day17 Day41
Day18 Day42
Day19 Day43
Day20 Day44
Day21 Day45
Day22 Day46
Day23 Day47
Day24 Day48
Date     :
Station:
                                                                                       Signature of the Guide:
                 Signature of the Investigator:
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
FORM VIII – PATIENT INFORMATION SHEET
Name of Co- Investigator:A. Anitha
Name of the college: Govt. Siddha Medical College
Arumbakkam, Chennai-106.
INFORMATION  SHEET  FOR PATIENTS PARTICIPATING IN THE OPEN
CLINICAL TRIAL.
I, A.Anitha studying M.D (Siddha) at Govt Siddha Medical College, Chennai,
is doing a clinical trial on “THADIPPU PERUNOI (PSORIASIS)”. It is becoming a
most common disease, occurring throughout the world. In this regard, I am in need to
ask you few questions. I will maintain confidentiality of your comments and data
obtained. There will be no risk of disclosing your identity and no physical,
psychological or professional risk is involved by taking part in this study. Taking part
in this study is voluntary. No compensation will be paid to you for taking part in this
study.
           You can choose not to take part. You can choose not to answer a specific
question. There is no specific benefit for you if you take part in the study. However,
taking part in the study may be of benefit to the community, as it may help us to
understand the problem of defaulters and potential solutions.
      If you agree to be a participant in this study, you will be included in the study
primarily by signing the consent form and then you will be given the internal
medicine“Swarna Pushpa Rasa Chendhurum” (Internal drug) 130mg bid with honey
for 48 days.
The information I am collecting in this study will remain between you and the
Co- investigator (myself). I will ask you few questions through a questionnaire. I will
not write your name on this form. I will use a code instead.
The questionnaire will take approximately 20 minutes of your time.
If you wish to find out more about this study before taking part, you can ask
me all the questions you want or contact A.Anitha, PG Scholar cum Co- investigator
of this study, attached to Govt. Siddha Medical College, Chennai-106. You can also
contact the Member-secretary of Ethics committee, Govt Siddha Medical College,
Chennai.
«ÃÍ º¢ò¾ ÁÕòÐÅì ¸øæ¡¢,
«È¢»÷ «ñ½¡ ÁÕòÐÅÁ¨É, ¦ºý¨É-106
jbg;G ngUNeha; §¿¡öì¸¡É º¢ò¾ ÁÕó¾¢ý ெசௗ ண பரச ெச ர ,
ெவ ேவ ைதல ம ராணயாம
À¡¢¸¡¢ôÒò ¾¢È¨Éì ¸ñ¼È¢Ôõ ÁÕòÐÅ ¬öÅ¢ü¸¡É ¾¸Åø ÀÊÅõ.
¬Ã¡öîº¢Â¡Ç÷ ¦ÀÂ÷: ÁÕòÐÅ÷. அ.அ தா
¿¢ÚÅÉò¾¢ý ¦ÀÂ÷: «ÃÍ º¢ò¾ ÁÕòÐÅì¸øæ¡,¢
«ÕõÀ¡ì¸õ,
¦ºý¨É-106
«ÃÍ º¢ò¾ ÁÕòÐÅì¸øæ¡¢Â¢ø Àð¼ §ÁüÀÊôÒ ÀÂ¢ýÚ ÅÕõ ¿¡ý
ÁÕòÐÅ÷.அ.அ தா, jbg;G ngUNeha; ±ýÛõ §¿¡Â¢ø ÁÕòÐÅ ¬Ã¡öîº¢Â¢ø
®ÎÀðÎû§Çý.
jbg;G ngUNeha; – இ வ டவ வமான பைடகைள ேதாலி
உ டா §¿¡ö ஆ , ேம அ , சிவ , ெசதி க , உதிர ஆகிய
றி ண கைள உ டா ..
þÐ ÀÃÅìÜÊÂ §¿¡ö «øÄ.
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ º¢Ä §¸ûÅ¢¸¨Çì§¸ð¸×õ, §¾¨ÅÂ¡É ¬öÅ¸ô
ÀÃ¢§º¡¾¨ÉìÌ ¾í¸¨Ç ¯ðÀÎò¾×õ ¯û§Çý.
þó¾ ¬Ã¡öîº¢ìÌ ¾¡í¸û Å¢ÕôÀò¾¢ý §ÀÃ¢ø ¯ðÀÎõ Àðºò¾¢ø
¯ûÁÕó¾¡¸ ெசௗ ண ப ரச ெச ர 130 மி¸¢ §¾É¢ø 2 §Å¨Ç (¸¡¨Ä,
Á¡¨Ä) ¯½×ìÌ À¢ý 48 ¿¡ð¸û ¯ð¦¸¡ûÇ §ÅñÎõ. ¦ÅÇ¢ §¿¡Â¡Ç÷¸û 7
¿¡ð¸ÙìÌ ´ÕÓ¨È ÁÕòÐÅÁ¨ÉìÌ ÅÃ §ÅñÎõ.
þó¾ ÁÕóÐ º¢ÈôÀ¡¸ jbg;G ngUNeha; §¿¡öì¸¡¸ «í¸£¸Ã¢ì¸ôÀð¼ º¢ò¾
ÁÕòÐÅ áÄ¢ø ÜÈôÀðÎûÇÐ.
þó¾ ¬Ã¡öîº¢Â¢ø ¾í¸¨Ç «ÛÁ¾¢ò¾ À¢ÈÌ ¯í¸ÙìÌ Å¢ÕôÀõ
þø¨Ä¦ÂÉ¢ø ±ô§À¡Ð §ÅñÎÁ¡É¡Öõ ¬Ã¡öîº¢Â¢ø þÕóÐ ல  ¦¸¡ûÇ
¯Ã¢¨Á ¯ûÇÐ.
þó¾ ¬Ã¡öîº¢ ºõÀó¾Á¡¸ §¿¡Â¢ý ¾ý¨Á ÀüÈ¢Ôõ ÁüÈ Å¢ÀÃí¸ÙìÌõ
¬Ã¡öîº¢Â¡ÇÃ¡É ÁÕòÐÅ÷:அ.அ தா (Àð¼ §ÁüÀÊôÀ¡Ç÷ சிற ÁÕòÐÅ
Ð¨È) «Å÷¸¨Ç ±ó¾ §¿Ãò¾¢Öõ ¦¾¡¼÷Ò ¦¸¡ûÇÄ¡õ ¨¸ô§Àº¢ ±ñ: 8940220224
 §ÁÖõ þó¾ ¬Ã¡öîº¢ìÌ ¾ì¸ «ÛÁ¾¢î º¡ýÚ (IEC) ¦ÀÈôÀðÎûÇÐ.
§ÁÖõ ¯½× Ó¨ÈÂ¢ø ÁÕòÐÅÃ¡ø ÜÈôÀÎõ Àò¾¢Âõ ¸¡ìÌÁ¡Ú
«È¢×Úò¾ ÀÎ¸¢ÈÐ.
þÐ ºõÀó¾Á¡É ¾í¸ÇÐ «¨ÉòÐ Å¢ÅÃí¸Ùõ Ã¸º¢ÂÁ¡¸ ¨Åì¸ôÀÎõ
±É ¯Ú¾¢ «Ç¢ì¸¢§Èý.
þ¾¢ø ÀÂ½ôÀÊ Ó¾Ä¢Â ±ó¾ ¯¾Å¢ò ¦¾¡¨¸Ôõ ÅÆí¸ô À¼Á¡ð¼¡Ð.
þó¾ ¬Ã¡öîº¢Â¢ý §À¡Ð ¯¼ÖìÌ §ÅÚ À¡¾¢ôÒ ²üÀÎõ Àðºò¾¢ø «È¢»÷
«ñ½¡ ÁÕòÐÅÁ¨ÉÂ¢ø, ¾ì¸ º¢¸¢î¨º «Ç¢ì¸ôÀÎõ.
GOVERNMENT SIDDHA MEDICAL COLLEGE
ARIGNAR ANNA GOVERNMENT HOSPITAL OF INDIAN MEDICINE
CHENNAI – 600 106
                POST GRADUATE DEPARTMENT OF SIRAPPU MARUTHUVAM
PRINICIPAL INVESTIGATOR: Dr.A.Anitha REG NO:
AN OPEN COMPARATIVE CLINICAL EVALUATION ON “THADIPPU
PERUNOI” (PSORIASIS) WITH SIDDHA TRIAL DRUGS “SWARNA
PUSHPA RASA CHENDHURAM” (INT), “VETTIVER THAILAM (EXT)’’
AND “PRANAYAMAM”.
FORM IX - DIETARY ADVICE FORM
§º÷ì¸ ÜÊÂ ¯½×¸û:
¸¡ö¸û:
ÓÕí¨¸À¢ïÍ,
«Å¨ÃÀ¢ïÍ,
À¢Ãñ¨¼,
¸¡Ãð,
À£ðåð.
¸£¨Ã¸û:
¸Ã¢º¡¨Ä,
¦À¡ýÉ¡í¸ñ½¢,
Á½ò¾ì¸¡Ç¢,
ÓÕí¨¸¸£¨Ã,
Àº¨Ä¸£¨Ã,
º¢Ú¸£¨Ã,
¸È¢§ÅôÀ¢¨Ä,
¦¸¡ò¾ÁøÄ¢.
Ò¾¢É¡.
ÀÆí¸û:
Á¡Ð¨Ç,
¬ôÀ¢û,
Å¡¨Æ,
§ÀÃ£î¨º,
«ò¾¢,
¾¢Ã¡ð¨º,
¦¸¡öÂ¡
¿¡Åø,
ºô§À¡ð¼¡,
¯Ä÷ ¾¢Ã¡ð¨º.
¾¡É¢Âí¸û
Ó¨Ç ¸ðÊÂ ÀÂ¢÷ Å¨¸¸û,
§º¡Â¡À£ýŠ, ¦Åó¾Âõ.
«¨ºÅõ:
¦ÅûÇ¡ðÎ¸È¢ ®Ãø,
±ÖõÒÁˆ¨ƒ,
ÁüÈ¨Å:
À¨É ¦ÅøÄõ
À¡ø
¾Å¢÷ì¸ §ÅñÊÂ¨Å¸û:
§¸¡Æ¢ì¸È¢, ¿ñÎ, ¸ÕÅ¡Î,
§Å÷ì¸¼¨Ä,
±ûÙ,
ÀôÀ¡Ç¢,
«ýÉ¡º¢,
ÒÇ¢ôÒ ¦À¡Õû¸û
±ÖÁ¢î¨º,
¾ì¸¡Ç¢,
ÒÇ¢ôÒ ¾Â¢÷,
°Ú¸¡ö,
¦Àñ§À¡¸õ,
¦ÅüÈ¢¨Ä,À¡ìÌ ,
Ò¨¸Â¢¨Ä ,
ÁÐ «ÕóÐ¾ø .
  
PASI SCORE FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) &PRANAYAMAN 
S. 
NO 
O.P 
NO 
EH IH DH AH EU IU DU AU ET IT DT AT EL IL DL AL TOTAL 
 
B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A 
1 1283 0 2 0 1 0 0 0 0 4 1 4 2 3 4 3 2 0 0 0 0 0 0 0 0 3 0 2 1 3 2 3 1 16.2 4.0 
2 1162 3 1 2 2 2 2 3 2 1 1 3 2 2 0 2 2 2 0 0 0 0 0 0 0 3 1 2 1 2 1 3 2 31.8 4.6 
3 4228 2 1 4 1 0 1 3 2 3 2 2 1 3 1 2 2 3 1 4 2 3 2 2 1 3 1 1 0 3 0 3 1 19.4 4.1 
4 5002 4 2 4 2 4 1 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.8 1.0 
5 5104 3 2 3 2 3 2 4 2 2 1 3 2 4 2 3 2 3 1 4 2 3 1 3 2 2 1 2 1 2 1 2 1 22.8 6.8 
6 4137 4 0 3 0 3 0 4 0 1 0 2 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.8 0 
7 1994 0 1 0 2 0 2 0 2 4 2 3 2 4 2 4 2 0 0 0 0 0 0 0 0 4 2 4 2 4 2 5 2 32.8 8.2 
8 8354 0 0 0 0 0 0 0 0 4 0 3 0 3 0 4 0 0 0 0 0 0 0 0 0 4 0 4 0 4 0 4 0 27.2 0 
9 5013 2 0 4 1 1 1 3 2 4 0 3 1 2 2 3 2 2 0 4 1 3 2 2 2 3 0 2 0 4 0 5 2 30.9 3.4 
10 2912 2 1 3 1 4 1 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2.7 0.6 
11 9115 3 0 3 0 2 0 2 0 2 1 3 2 3 1 3 2 4 0 3 0 3 0 4 0 4 1 4 2 4 1 5 2 42.4 4.8 
12 4995 2 0 3 1 3 1 2 2 2 0 1 1 3 2 2 2 2 0 4 1 1 2 2 1 3 0 4 2 2 2 4 2 22.6 5.7 
13 3365 3 1 4 1 2 1 4 2 1 1 3 1 2 2 1 1 3 1 4 0 2 0 3 2 3 0 3 0 3 0 4 1 27.3 2 
14 3435 4 3 4 0 4 3 5 1 0 0 0 1 0 2 0 1 3 0 3 2 3 0 3 2 0 2 0 1 0 0 0 1 12 8.3 
15 7638 0 0 0 0 0 0 0 0 3 0 3 0 2 0 3 0 0 0 0 0 0 0 0 0 2 0 3 0 2 0 3 0 14.4 0 
16 4986 3 1 2 1 4 2 3 2 2 1 2 1 3 2 2 2 3 1 2 1 2 1 3 2 2 1 3 2 2 1 3 2 20.2 7.4 
17 5087 4 0 4 1 4 2 5 2 4 0 4 1 4 2 5 2 4 1 4 2 4 0 5 2 3 0 2 1 2 1 2 1 41.6 4.4 
18 1670 4 0 4 0 4 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.8 0 
19 3133 0 0 0 0 0 0 0 0 3 1 2 1 3 1 2 1 0 0 0 0 0 0 0 0 4 2 3 1 2 0 3 1 14 1.8 
20 7137 2 0 2 0 2 0 2 0 3 0 2 0 2 0 3 0 3 0 2 0 2 0 3 0 3 0 2 0 3 0 3 0 21.3 0 
 PASI SCORE FOR OPD PATIENTS TREATED WITH  
SWARNA PUSHPA RASA CHENDHURAM (INT), VETTIVER THYLAM (EXT) 
 
S. 
NO 
OP. 
NO 
EH IH DH AH EU IU DU AU ET IT DT AT EL IL DL AL TOTAL 
 
B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A 
1 9658 0 0 0 0 0 0 0 0 3 0 4 0 3 0 2 0 1 0 3 0 4 0 2 0 3 0 2 0 2 0 2 0 14.4 0 
2 7894 0 0 0 0 0 0 0 0 4 1 4 2 3 2 4 2 0 0 0 0 0 0 0 0 3 1 2 2 3 1 4 2 21.6 5.2 
3 5612 4 0 4 2 4 1 5 2 4 0 4 1 4 2 5 2 4 0 4 3 4 2 5 2 4 0 4 3 4 2 5 3 60 10.8 
4 3012 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 4 0 2 0 4 0 3 0 2 0 1 0 2 0 15.6 0 
5 9632 4 2 4 1 3 1 5 3 0 0 0 0 0 0 0 0 3 1 3 2 3 4 3 2 0 0 0 0 0 0 0 0 13.6 5.4 
6 5284 0 0 0 0 0 0 0 0 4 0 3 0 4 0 3 0 0 0 0 0 0 0 0 0 4 0 4 0 4 0 3 0 21 0 
7 1478 0 0 0 0 0 0 0 0 3 1 2 0 3 1 4 2 2 0 4 0 3 0 2 2 0 0 0 0 0 0 0 0 11.8 0.8 
8 4563 4 0 1 0 3 0 1 0 3 0 3 2 2 2 3 2 1 0 3 0 1 0 2 0 4 2 2 1 2 1 1 1 11.8 3.2 
9 2354 4 1 4 2 4 2 5 3 4 1 4 1 4 1 5 2 4 1 4 1 4 1 5 2 4 1 4 1 4 1 5 2 60 6.4 
10 6589 3 0 4 2 3 2 3 2 4 2 4 1 4 2 5 2 4 1 4 2 4 1 5 3 4 0 4 3 4 1 5 1 57 7.0 
11 1452 2 0 2 0 3 0 4 2 2 0 1 0 3 0 3 1 2 0 3 1 2 0 3 2 2 0 2 0 3 0 3 2 21.1 0.6 
12 6325 2 1 3 1 2 2 3 2 2 0 2 0 4 0 2 0 2 2 3 1 4 2 3 2 1 0 1 1 2 1 4 1 23.5 4.6 
13 7896 0 0 0 0 0 0 0 0 3 0 4 0 2 0 3 0 4 0 3 0 2 0 2 0 0 0 0 0 0 0 0 0 10.8 0 
14 7852 0 1 0 2 0 0 0 1 4 0 3 0 4 0 4 0 0 2 0 1 0 0 0 2 3 2 4 1 2 3 4 2 23.2 4.8 
15 2365 2 0 2 0 2 0 2 0 3 0 2 0 4 0 3 0 3 0 1 0 2 0 2 0 4 0 3 0 2 0 4 0 24.6 0 
16 2031 0 2 0 3 0 2 0 2 2 0 2 0 2 0 2 0 0 0 0 0 0 0 0 0 2 0 3 0 3 0 2 0 8.8 2.8 
17 9630 3 0 2 0 1 0 3 0 2 0 2 0 2 0 3 0 3 0 2 0 2 0 3 0 3 0 2 0 3 0 3 0 21.3 0 
18 7456 2 0 3 0 0 0 0 1 0 2 4 2 3 2 2 2 0 0 0 0 0 0 0 0 3 0 2 0 4 0 2 0 14.4 6.4 
19 2368 2 1 3 1 3 1 2 1 3 0 3 1 2 1 2 1 4 0 3 1 3 0 2 1 2 0 2 1 3 2 2 1 16.4 2.2 
20 3148 0 0 0 0 0 0 0 0 4 1 3 1 3 2 3 1 0 0 0 0 0 0 0 0 3 1 3 3 2 1 4 2 18.8 4.8 
 PASI SCORE FOR OPD PATIENTS TREATED WITH 
 VETTIVER THYLAM (EXT) &PRANAYAMAM 
 
 
S. 
NO 
OP. 
NO 
EH IH DH AH EU IU DU AU ET IT DT AT EL IL DL AL TOTAL 
 
B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A B A 
1 5086 2 0 3 0 1 0 1 0 3 2 4 2 3 2 2 2 0 0 0 0 0 0 0 0 3 2 2 2 4 3 2 2 14.4 8 
2 5268 2 1 3 1 3 1 2 1 3 0 3 1 2 1 2 1 4 0 3 1 3 0 2 1 2 0 2 1 3 2 2 1 16.4 2.2 
3 9920 0 0 0 0 0 0 0 0 4 1 3 1 3 2 3 1 0 0 0 0 0 0 0 0 3 1 3 3 2 1 4 2 18.8 4.8 
4 4570 0 2 0 1 0 0 0 0 4 1 4 2 3 4 3 2 0 0 0 0 0 0 0 0 3 0 2 1 3 2 3 1 16.2 4.0 
5 5460 3 1 2 2 2 2 3 2 1 1 3 2 2 0 2 2 2 0 0 0 0 0 0 0 3 1 2 1 2 1 3 2 31.8 4.6 
6 5171 2 1 4 1 0 1 3 2 3 2 2 1 3 1 2 2 3 1 4 2 3 2 2 1 3 1 1 0 3 0 3 1 19.4 4.1 
7 7369 4 2 4 2 4 1 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4.8 1.0 
8 3107 3 2 3 2 3 2 4 2 2 1 3 2 4 2 3 2 3 1 4 2 3 1 3 2 2 1 2 1 2 1 2 1 22.8 6.8 
9 3109 4 0 4 2 4 1 5 2 4 0 4 1 4 2 5 2 4 0 4 3 4 2 5 2 4 0 4 3 4 2 5 3 60 10.8 
10 2798 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 4 0 2 0 4 0 3 0 2 0 1 0 2 0 15.6 0 
11 1392 4 1 4 1 3 2 5 1 0 0 0 0 0 0 0 0 3 1 3 1 3 1 3 2 0 0 0 0 0 0 0 0 13.6 6.4 
12 2102 3 0 4 2 3 2 3 2 4 2 4 1 4 2 5 2 4 1 4 2 4 1 5 3 4 0 4 3 4 1 5 1 57 7.0 
13 769 2 0 2 0 3 0 4 2 2 0 1 0 3 0 3 1 2 0 3 1 2 0 3 2 2 0 2 0 3 0 3 2 21.1 0.6 
14 2580 2 1 3 1 2 2 3 2 2 0 2 0 4 0 2 0 2 2 3 1 4 2 3 2 1 0 1 1 2 1 4 1 23.5 4.6 
15 6566 0 0 0 0 0 0 0 0 3 0 4 0 2 0 3 0 4 0 3 0 2 0 2 0 0 0 0 0 0 0 0 0 10.8 0 
16 5931 0 0 0 0 0 0 0 0 4 0 3 0 4 0 4 0 0 0 0 0 0 0 0 0 3 2 4 1 2 3 4 2 23.2 4.8 
17 3124 3 0 2 0 1 0 3 0 2 0 2 0 2 0 3 0 3 0 2 0 2 0 3 0 3 0 2 0 3 0 3 0 21.3 0 
18 5469 3 0 3 0 2 0 2 0 2 1 3 2 3 1 3 2 4 0 3 0 3 0 4 0 4 1 4 2 4 1 5 2 42.4 4.8 
19 5224 2 0 3 1 3 1 2 2 2 0 1 1 3 2 2 2 2 0 4 1 1 2 2 1 3 0 4 2 2 2 4 2 22.6 5.7 
20 3001 0 0 0 0 0 0 0 0 4 1 3 1 3 2 3 1 0 0 0 0 0 0 0 0 3 1 3 3 2 1 4 2 18.8 4.8 









